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ABSTRACT OF THE DISSERTATION 
Discovery and Characterization of Novel Polyomaviruses in Humans 
by 
Erica Anne Siebrasse 
Doctor of Philosophy in Biology and Biomedical Sciences 
Washington University in St. Louis, 2014 
Professor David Wang, Chair 
 
 
 The family Polyomaviridae is comprised of small, double-stranded DNA viruses of 
approximately 5,000 base pairs. Two polyomaviruses are well-established human pathogens and 
cause significant morbidity and mortality in immunocompromised patients. These viruses were 
discovered in the 1970s, but the last seven years have seen an explosion of novel human 
polyomavirus discoveries. The work described here seeks to address two questions:  “Are there 
additional, novel polyomaviruses infecting humans?” and “Do these polyomaviruses cause 
disease in their human hosts?” The discovery of an additional novel polyomavirus, MW 
polyomavirus (MWPyV), is described. MWPyV was discovered in the stool of a healthy child 
from Malawi but was subsequently detected from pediatric patients with diarrhea in St. Louis, 
Missouri. As a step toward determining the pathogenicity of WU polyomavirus (WUPyV) and 
KI polyomavirus (KIPyV) in humans, immunohistochemical studies were completed to identify 
their tissue and cell tropisms. Both viruses were detected in alveolar macrophages, and WUPyV 
was also detected in respiratory epithelial cells and in cells associated with mucin-producing 
cells in the trachea. In addition, KIPyV was detected in the spleen. The immunocompromised 
state of the patients studied raises important questions about the role of immunosuppression in 
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the pathogenesis of WUPyV and KIPyV. Finally, this work details ultimately unsuccessful 
attempts to establish a cell culture system for WUPyV, which would have provided a means to 
study viral biology and disease causality. Overall, these studies further our understanding of 
human polyomavirus biology and the role of WUPyV and KIPyV in human disease and provide 
additional avenues for future research to further address these important questions. 
 1 
 
CHAPTER 1 
 
Introduction 
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OVERVIEW 
 
The work presented in Chapters 2-4 seeks to address two overarching questions:  “Are there 
additional novel polyomaviruses infecting humans?” and “Do these polyomaviruses cause 
disease in their human hosts?” Before describing the research itself, it is important to place it in 
context within the field and provide background information for the relevant research topics I 
address. To this end, the Introduction has been broken into two sections, with the first addressing 
why and how we search for novel viruses and the second describing the state of the 
polyomavirus field, focusing on what we knew when I began my work.  
 
SECTION I:  DISCOVERY OF NOVEL VIRUSES 
 Why is viral discovery important? Diseases of infectious etiology represented four of 
the top 10 causes of death worldwide in 2011 according to the World Health Organization (Table 
1) (1). These include lower respiratory infections, diarrheal diseases, HIV/AIDS and 
tuberculosis. While AIDS is caused by the human immunodeficiency virus (HIV) and 
tuberculosis by Mycobacterium tuberculosis, lower respiratory infections and diarrheal diseases 
are both caused by a number of different pathogens. There are also non-infectious causes of 
diarrhea. Remarkably, approximately 30% of respiratory illnesses (2) and 40% of diarrhea cases 
(3) are of unknown etiology. This amounts to approximately two million respiratory- or diarrhea-
related deaths every year. In other words, we have no idea what causes a significant proportion 
of two major diseases. These deaths can likely be attributed to a number of different causes, 
including non-infectious, bacterial and fungal. However, we hypothesize that unrecognized 
viruses play a significant role in respiratory and diarrheal diseases.  
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Table 1.1. Top 10 causes of death worldwide in 2011. Reproduced from (1). Diseases of 
infectious etiology are highlighted in gray. 
World Deaths in millions % of deaths 
Ischemic heart disease 7.25 12.8% 
Stroke and other cerebrovascular disease 6.15 10.8% 
Lower respiratory infections 3.46 6.1% 
Chronic obstructive pulmonary disease 3.28 5.8% 
Diarrheal diseases 2.46 4.3% 
HIV/AIDS 1.78 3.1% 
Trachea, bronchus, lung cancers 1.39 2.4% 
Tuberculosis 1.34 2.4% 
Diabetes mellitus 1.26 2.2% 
Road traffic accidents 1.21 2.1% 
 
 A number of viruses are already known to cause respiratory illness or diarrhea. The main 
viral causes of diarrhea include viruses in the families Reoviridae (especially rotavirus), 
Astroviridae, Caliciviridae (especially norovirus) and Adenoviridae. The most common illness 
most people experience, regardless of their demographics, is acute respiratory infections (ARTI) 
(4). The predominant viral causes are rhinoviruses, influenza viruses, coronaviruses, 
parainfluenza viruses, respiratory syncytial virus and adenoviruses (4). Several additional causes 
of respiratory illness have been recently identified, and these include human metapneumovirus, 
and the novel human coronaviruses [severe acute respiratory syndrome coronavirus (SARS-
CoV) (5), Middle East respiratory syndrome coronavirus (MERS-CoV) (6), NL63 and HKU1 
(7)]. Other viruses, including WU polyomavirus (WUPyV) and KI polyomavirus (KIPyV), 
which are discussed in depth below, may also have roles in respiratory tract infections.  
 In addition to respiratory and diarrheal infections, other diseases are also of unknown 
etiology but thought to have infectious origins. For example, post-transplant infections are a 
leading cause of morbidity and mortality in cardiac transplant patients. Infections are the leading 
cause of death in adults and account for 15-34% of deaths in children from 31 days to one year 
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post-transplant (8-10). Of these deaths, approximately 30-40% are of diagnosed viral etiology (9, 
11). Viral infections have also been postulated to contribute to at least a fraction of other adverse 
events, including graft loss, acute graft rejection and cardiac allograft vasculopathy. Several 
groups are attempting to identify additional viral agents in this vulnerable population, but none 
are looking for novel viruses, which is the subject of continued research in our lab. In fact, the 
effects of this type of research can be seen in the recent discovery of a novel polyomavirus, 
Trichodysplasia spinulosa-associated polyomavirus (TSPyV), in a heart transplant recipient. This 
discovery led to the successful treatment of the patient’s Trichodysplasia spinulosa, a disease 
strongly associated with transplantation and immunosuppression, with topical cidofovir and will 
undoubtedly influence future cases (12). This is but one example of diseases thought to be of 
infectious etiology where no agents have yet been identified.  
 Viruses are also known to contribute to human cancers. This has been reviewed 
extensively (Table 1.2) (13). There are also a number of other cancers that are hypothesized to 
have viral etiologies, including chronic lymphocytic leukemia (14), among many others. 
Furthermore, some viruses have already been associated with cancers, but causation has not been 
definitively shown. Viral discovery methods are invaluable tools to explore types of cancer 
where viral causation is suspected. For example, Merkel cell carcinoma polyomavirus (MCPyV) 
was discovered recently and found to be clonally integrated into a large proportion of Merkel cell 
carcinomas (MCC) (15). While the majority of the population is seropositive for MCPyV, only a 
small number of people develop MCC each year. Determining how the virus induces 
tumorigenesis and risk factors for the disease will be critical in preventing it. For all of the 
potential disease states discussed here—respiratory and diarrheal diseases, infectious diseases of 
unknown etiology and cancers with possible viral contributions—it is impossible to develop 
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treatment and prevention methods to minimize their morbidity and mortality without the 
identification of a causative agent.  
  
Table 1.2. The human cancer viruses. Reproduced from (13) with permission from the publisher 
under license 3394961343186. 
Virus Notable cancers Reference 
Epstein-Barr virus (EBV) Most Burkett’s lymphoma and nasopharyngeal 
carcinoma, most lymphoproliferative disorders, 
some Hodgkin's disease, some non-Hodgkin's 
lymphoma and some gastrointestinal lymphoma 
(16) 
Hepatitis B virus (HBV) Some hepatocellular carcinoma (17) 
Human T-lymphotropic virus-
1 (HTLV-1) 
Adult T cell leukemia (18) 
Human papillomavirus (HPV) Most cervical and penile cancers and some other 
anogenital and head and neck cancers 
(19, 20) 
Hepatitis C virus (HCV) Some hepatocellular carcinoma and some 
lymphomas 
(21) 
Kaposi’s sarcoma herpesvirus 
(KSHV) 
Kaposi’s sarcoma, primary effusion lymphoma 
and some multicentric Castleman’s disease 
(22) 
Merkel cell polyomavirus 
(MCPyV) 
Most Merkel cell carcinoma (15) 
 
 Methods of viral discovery. There are a number of methods available for discovery of 
novel viruses. Many viruses were discovered using “classical methods,” most of which rely on 
growth of the virus in cell culture after inoculation with patient samples of interest. As many 
viruses are difficult to grow, this method biases discovery toward easily cultivatable viruses. 
Before the advent of molecular techniques, viruses that could be grown were classified based on 
characteristic such as their size and morphology by electron microscopy, serologic profile and 
the type of cells in which they grew. This created an issue, as many viruses grew or looked alike, 
although they ultimately represented distinct viral species and caused different illnesses.  
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With the development of molecular methods such as PCR, new approaches to viral 
discovery based on the detection of viral nucleic acids were created. PCR increased the 
sensitivity, specificity and throughput of identifying a specific viral agent. As many viruses share 
conserved genes (i.e. RNA-dependent RNA polymerase), primers targeting these areas could be 
developed to search for related but new viruses. This method is termed “consensus PCR” and is 
still widely used to discover novel viruses. Some examples of the applications of consensus PCR 
are the discoveries of human polyomavirus 7 (HPyV7), human polyomavirus 9 (HPyV9) and 
human polyomavirus 12 (HPyV12) (23-25). As with most of the molecular methods of discovery 
described here, consensus PCR is dependent on having sufficient sequence to identify shared 
sequences. In addition, it is a candidate-dependent approach, meaning the investigator must 
choose a specific candidate virus or viral family in order to use this method. This represents a 
serious challenge if the initial hypothesis is wrong. 
 Microarrays have been utilized for viral discovery, although more recent technologies 
have eclipsed their capacity. Pan-viral microarrays use oligonucleotide probes targeting highly 
conserved sequences from many viral families. For example, the first report of the ViroChip had 
1,600 unique probes targeting approximately 140 viral genomes (26). A more recent version had 
20,000 probes. This technology facilitated high throughput screening of a particular sample for 
many different viruses. While this method was also limited by its reliance on sequence similarity, 
it was candidate-independent.  
Perhaps the biggest leap forward in viral discovery technologies came with the 
development of high throughput sequencing. This began with high throughput Sanger 
sequencing where 96 clones could be sequenced in parallel. Both WUPyV and KIPyV were 
discovered using this approach (27, 28). With the advent of next generation sequencing 
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technologies, including the 454 (Roche) and Illumina platforms, the number of sequencing reads 
obtained from a single run was vastly increased. Our lab currently uses the Illumina MiSeq 
platform, which generates approximately 10 million paired 250 base pair reads, allowing for 
assembly of contigs of approximately 450 nucleotides. The sheer volume of reads produced by 
these systems requires sophisticated computational analysis. Our lab utilizes a computational 
viral discovery pipeline (Figure 1.1) that separates reads with identity to known viral sequences 
from reads with similarity to other hosts. This pipeline is described in detail in Chapter 2. If 
evidence of a novel virus is found (i.e. the read has low identity to a known virus), sequences 
from the candidate virus are assembled to generate a partial genome. Full genomes are then 
determined using a combination of molecular approaches depending on the type of virus. A 
number of viruses have been discovered using these methods, including MW polyomavirus 
(MWPyV), the subject of Chapter 2. 
 
Figure 1.1. Virus detection & discovery pipeline. 
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 Determination of disease causality. Once a novel virus is discovered, determining if it 
causes a particular disease is an important, albeit often difficult, question to answer. The gold 
standard for establishing disease causality is to fulfill Koch’s postulates, which are summarized 
below: 
1. The parasite occurs in every case of the disease in question and under circumstances 
which can account for the pathological changes and clinical course of the disease. 
2. The parasite occurs in no other disease as a fortuitous and nonpathogenic parasite. 
3. After being fully isolated from the body and repeatedly grown in pure culture, the 
parasite can induce the disease anew. (29) 
As viruses cannot, by definition, be grown in pure culture, Koch’s postulates must be modified to 
ascribe disease causality to a virus. This typically means the virus must be grown in cell culture. 
As previously mentioned, growing many viruses is difficult, and some viruses, such as norovirus, 
have yet to be cultured. Others have proposed variations of Koch’s postulates which bypass the 
need for cell culture, including David Relman and David Fredericks: 
1. A nucleic acid sequence belonging to a putative pathogen should be present in most 
cases of an infectious disease. Microbial nucleic acids should be found preferentially in 
those organs or gross anatomic sites known to be diseased (i.e., with anatomic, 
histologic, chemical, or clinical evidence of pathology) and not in those organs that lack 
pathology. 
2. Fewer, or no, copy numbers of pathogen-associated nucleic acid sequences should 
occur in hosts or tissues without disease. 
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3. With resolution of disease (for example, with clinically effective treatment), the copy 
number of pathogen-associated nucleic acid sequences should decrease or become 
undetectable. With clinical relapse, the opposite should occur. 
4. When sequence detection predates disease, or sequence copy number correlates with 
severity of disease or pathology, the sequence-disease association is more likely to be a 
causal relationship. 
5. The nature of the microorganism inferred from the available sequence should be 
consistent with the known biological characteristics of that group of organisms. When 
phenotypes (e.g., pathology, microbial morphology, and clinical features) are predicted 
by sequence-based phylogenetic relationships, the meaningfulness of the sequence is 
enhanced. 
6. Tissue-sequence correlates should be sought at the cellular level: efforts should be 
made to demonstrate specific in situ hybridization of microbial sequence to areas of 
tissue pathology and to visible microorganisms or to areas where microorganisms are 
presumed to be located. 
7. These sequence-based forms of evidence for microbial causation should be 
reproducible. (29) 
Despite the difficulty of determining disease causality, this research can have profound effects on 
morbidity and mortality of the disease. For example, identification of JC polyomavirus (JCPyV) 
as the etiological agent of progressive multifocal leukoencephalopathy (PML) allowed the 
development of screening strategies to identify affected individuals. In some cases, the patient’s 
immunosuppression can now be modulated following detection of the virus to decrease 
mortality. 
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 In conclusion, there are many suspected diseases of infectious etiology for which a 
candidate agent is undefined. Approximately two million worldwide deaths from respiratory and 
diarrheal diseases fall into this category as do a number of other diseases and cancers. While 
various viral discovery techniques have been utilized for decades, the past ten years have seen 
the emergence of increasingly high throughput, candidate-independent technologies, which have 
been used to discover a plethora of new viruses. Even newer methods are currently in 
development to identify viruses with no sequence homology to known viruses. Pandemics such 
as SARS and emerging viruses such as MERS teach us that new viruses are constantly emerging 
and can have severe impacts on both human health and global economics, making viral 
discovery a necessity. 
 
SECTION II:  THE POLYOMAVIRIDAE 
 General characteristics. Polyomaviruses are small circular, double-stranded DNA 
viruses that form non-enveloped virions of approximately 40-45 nm in diameter. Mature viral 
particles have a density of approximately 1.34 g/mL in cesium chloride, while empty capsids 
have a density of 1.29 g/mL (30). The icosahedral viral capsid is comprised of 72 pentamers in a 
T=7 lattice arrangement and surrounds one copy of the genome, which averages approximately 
5,000 base pairs. The capsid is complexed with the cellular histones H2A, H2B, H3 and H4. The 
genome can be divided into three parts (Figure 1.2):  the regulatory region, the early region and 
the late region. The regulatory region, also called the noncoding control region (NCCR), contains 
the origin of replication and promoters for the early and late regions. Transcription occurs 
bidirectionally from the regulatory region. The early region encodes the large tumor antigen 
(LTAg) and small tumor antigen (STAg), which are expressed prior to viral replication. The late 
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region is expressed after viral replication has begun and encodes the structural proteins VP1, 
VP2 and VP3. VP1, the major structural protein, comprises over 70% of the viral particle and is 
the antigenic portion of the virus to which most natural antibodies are made (31). Some 
polyomaviruses encode an additional one to four proteins of varying function, although the 
viruses described in this dissertation (MWPyV, WUPyV and KIPyV) do not. 
 
Figure 1.2. Schematic representation of the WUPyV genome, including the early region, late 
region and NCCR. Reproduced from (27).  
 
 
Viral life cycle. The polyomavirus life cycle (Figure 1.3) begins when the virus attaches 
and enters the host cell. While the receptors for most polyomaviruses, including WUPyV, KIPyV 
and MWPyV, are still unknown, BKPyV, JCPyV, SV40, murine polyomavirus (MPyV) and 
Merkel cell carcinoma polyomavirus (MCPyV) all are reported to use gangliosides. In addition, 
JCPyV requires the serotonin receptor 5HT-2a as a coreceptor, and some studies on SV40 have 
supported its use of MHC class I as a receptor (32). Following attachment, polyomaviruses enter 
the cell via caveolae-mediated endocytosis (SV40) or clathrin-mediated endocytosis (JCPyV) 
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(30). The exact mechanism of intracellular trafficking and uncoating has yet to be deciphered, 
but the virus is eventually delivered to the nucleus, where transcription of the early region 
begins. Once LTAg protein is made, it autoregulates the early promoter and drives simultaneous 
replication of the viral genome and transcription of the late region. After the structural proteins 
have accumulated in the nucleus, the virion is assembled. It is unclear how the virus exits the 
cell, as different studies have demonstrated both lytic release and shedding from intact cells (30). 
Polyomavirus genomes are relatively stable over time, with WUPyV having low nucleotide 
variation of 0-1.2% (33). 
 
Figure 1.3. The polyomavirus life cycle. Figure is used with permission from Anne M. Gaynor. 
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Polyomaviruses, human disease and virus tropism. Polyomaviruses infect a wide 
range of mammalian and avian hosts, including non-human primates, cattle, rabbits, several 
small rodent species, various bird species, bats, sea lions, dolphins and humans, among others. 
There were nine fully sequenced human polyomaviruses when this work was begun, including 
BKPyV, JCPyV, WUPyV, KIPyV, MCPyV, human polyomavirus 6 (HPyV6), HPyV7, TSPyV 
and HPyV9. BKPyV and JCPyV were both discovered in 1971. BKPyV causes BK nephropathy 
in kidney transplant recipients, which can lead to graft rejection, and hemorrhagic cystitis in 
bone marrow transplant recipients; JCPyV is the etiological agent of PML, a rare neurological 
condition (30).  
No new human polyomaviruses were identified until the discovery of WUPyV and 
KIPyV in 2007 (27, 28). Both were discovered in respiratory tract secretions from patients with 
respiratory illness. A more thorough background on these viruses is included below. The 
discovery of these viruses re-invigorated the Polyomaviridae field and study of the family’s role 
in human disease (34). MCPyV was discovered clonally integrated into 80% of MCCs in 2008 
(15). MCC is a rare but very aggressive skin cancer. Subsequent reports have indicated the virus 
may play a role in all MCCs, although this is still debated (35). MCPyV was the first human 
polyomavirus to be definitively tied to a human cancer. There are numerous reports linking 
JCPyV and BKPyV to various cancers, but an abundance of conflicting data exists (36), and 
there is still no consensus in the field as to whether these viruses cause cancers. Following the 
discovery of MCPyV, HPyV6 and HPyV7 were discovered in skin swabs from healthy 
volunteers (23). HPyV6 was discovered using rolling circle amplification (RCA), and consensus 
PCR was used to find HPyV7. No diseases have been associated with either virus. TSPyV was 
also detected using RCA in skin spicules from a patient with Trichodysplasia spinulosa, a rare 
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skin condition, exclusively seen in immunocompromised patients (12). Finally, the discovery of 
HPyV9 also used consensus PCR and found the virus in serum from a kidney transplant recipient 
(25). Again, no diseases have been associated with HPyV9. At the time the research in this 
dissertation began, these were the only known human polyomaviruses. The discovery of 
MWPyV, the tenth human polyomavirus, and its role in human disease is described in Chapter 2. 
Three additional human polyomaviruses have since been identified, and these are described in 
the Discussion. None of the other three new viruses has been definitively associated with disease, 
although some evidence exists for New Jersey polyomavirus (NJPyV) (37). A timeline of all 
discoveries is depicted in Figure 1.4. 
 
Figure 1.4. Timeline of human polyomavirus discoveries. Viruses in red are the subject of this 
dissertation. STL polyomavirus (STLPyV) (38). 
 
 
It is not currently known how any of the human polyomaviruses, including BKPyV and 
JCPyV, spread among humans, but their seroprevalence is generally quite high. Antibodies 
against BKPyV are detected in 82-99% of people, while the seroprevalence for JCPyV is 39-
81% (36). Several of the other human polyomaviruses also have high seroprevalences, including 
KIPyV (55-90%), WUPyV (69-98%) and MCPyV (60-81%) (36). The others are somewhat 
lower at 69% for HPyV6, 35% for HPyV7, 70% for TSPyV, 21-53% for HPyV9 and 17-23% for 
HPyV12 (24, 36). Studies to determine the seroprevalence of MWPyV and STLPyV are 
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ongoing. Following primary infection in childhood, BKPyV and JCPyV establish persistent 
latent infections in the kidneys but can periodically reactivate, leading to shedding of infectious 
virus in the urine (30). This may be a route of virus transmission. Primary infection and periodic 
reactivation are typically asymptomatic unless the host is immunocompromised, in which case 
life-threatening illness can occur.  
Following infection, both viruses spread efficiently within the human body and are 
detected in peripheral blood leukocytes (39) and in a variety of organs, including heart, spleen, 
lung, colon and liver (30). JCPyV has a well-established neurotropism and can also be identified 
in human tonsil stromal cells and in other cell types of the tonsils (30). Both BKPyV and JCPyV 
have been cultured in mammalian cells. JCPyV has limited cell specificity and can infect human 
glial cells and tonsillar stromal cells (40). BKPyV can infect a greater variety of cells, including 
African green monkey kidney cells, human embryonic kidney, human diploid lung fibroblasts, 
infant urothelial cells, human fetal brain cells, monkey kidney cells and human embryonic lung 
cells (41, 42). The other human polyomaviruses have been found in a variety of sample types 
(see Table 4.1), but little work has been done to establish their specific cell or tissue tropisms, 
although inflammatory monocytes (CD14+ CD16-) have been identified as a reservoir for 
MCPyV (43). No cell culture systems for the novel polyomaviruses have been reported to date, 
but a replication system similar to that described in Chapter 4 for WUPyV has been established 
for MCPyV (44).  
WU and KI polyomaviruses. WUPyV was discovered in a respiratory sample from a 
three-year-old Australian child with pneumonia (27). KIPyV was similarly found in pooled 
respiratory samples from patients with respiratory illness (28). Both viruses have since been 
detected by PCR in a variety of samples, including cerebrospinal fluid (CSF), tonsillar tissue, 
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whole blood, plasma, stool and lymph tissue (45, 46). As noted above, the majority of the 
population has generated antibodies against the viruses. Data also indicates WUPyV can 
establish a persistent infection; two pediatric transplant cases from St. Louis had sequential 
samples obtained over a period of several weeks that were positive for viral DNA (47). Although 
this data represents important preliminary results, it is still unknown whether WUPyV and 
KIPyV cause human disease. No specific cell or tissue tropisms have been identified for either 
virus, and a systematic search of human tissues has not been performed. Determining the cell and 
tissue tropism will help narrow down diseases potentially caused by WUPyV or KIPyV 
infection. Finally, no infectious cell culture system has been established for either virus to date, 
making the fulfillment of Koch’s postulates impossible. 
 
CONCLUSIONS 
The study of the 11 novel polyomaviruses is in its infancy, and little is known about their 
biology or ability to cause disease. In this dissertation, I took a multifaceted approach to gain a 
better understanding of the biology and potential roles in disease of WUPyV, KIPyV and 
MWPyV. 
Using the viral discovery techniques describe above, we discovered a novel polyomavirus 
in the stool of a child from Malawi, which we tentatively named MWPyV. The first aim of my 
work was to sequence and characterize the complete genome of MWPyV and determine its 
prevalence in humans. Obtaining a complete genome sequence is the first step in characterizing a 
novel virus and allowed me to determine its phylogenetic relationship to other family members, 
the size of its genome and its genomic organization. Obtaining the complete sequence was also 
prerequisite to downstream studies, including generation of a genomic clone. Prevalence studies, 
17 
 
such as those detailed here, address questions like, "Can we detect viral persistence over time?” 
and “Can we identify the virus in novel sample types?" Answers to these questions give us clues 
as to where in the body the virus resides and are a first step in identifying the virus’ cell and 
tissue tropism.  
An important step in establishing the role of WUPyV and KIPyV in human disease is to 
determine the viruses’ cell and tissue tropisms. The goal of this aim was to identify the kinds of 
tissues and the specific cell types within that are positive for WUPyV and KIPyV, which will 
help us better understand viral biology and possibly identify disease states associated with viral 
infection. I approached this step directly by using immunohistochemical methods to detect the 
viruses in human tissues and determine the specific cell types they infect.  
Many downstream studies of WUPyV biology are dependent on having a cell culture 
system for the virus, including identifying the viral receptor and studying its intracellular 
interactions. The gold standard approach to determining disease causality is the fulfillment of 
Koch's postulates, which by definition requires the virus be grown in culture. As no such system 
currently exists for WUPyV, it is a fundamental barrier to both establishing disease causality and 
exploring the basic biology of this virus. The final aim of this work was to establish an infectious 
cell culture system for WUPyV.  
While the three aims of this research were highly specific, they address the two 
overarching research questions presented at the beginning of this section:  “Are there additional, 
novel polyomaviruses infecting humans?” and “Do these polyomaviruses cause disease in their 
human hosts?” I address the first question in Chapter 2, where I detail the discovery and 
characterization of the novel polyomavirus MWPyV. The second question is addressed in 
Chapters 2 and 3, where I report the identification of specific cell types positive for WUPyV and 
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KIPyV, describe the cases of several virus-positive patients and detail attempts to grow WUPyV 
in cell culture. Finally, in the Discussion, I broadly summarize these findings and return back to 
discuss the two questions noted above. 
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CHAPTER 2 
 
 
Identification of MW polyomavirus, a novel polyomavirus in human stool 
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ABSTRACT 
We have discovered a novel polyomavirus present in multiple human stool samples. The virus 
was initially identified by shotgun pyrosequencing of DNA purified from virus-like particles 
isolated from a stool sample collected from a healthy child from Malawi. We subsequently 
sequenced the virus' 4,927 bp genome, which has been provisionally named MW polyomavirus 
(MWPyV). The virus has genomic features characteristic of the family Polyomaviridae but is 
highly divergent from other members of this family. It is predicted to encode the early proteins 
large T antigen and small T antigen and the structural proteins VP1, VP2 and VP3. A real-time 
PCR assay was designed and used to screen 514 stool samples from children with diarrhea in St. 
Louis, Missouri; 12 specimens were positive for MWPyV. Comparison of the whole genome 
sequences of the index Malawi case and one St. Louis case demonstrated that the two strains of 
MWPyV varied by 5.3% at the nucleotide level. The number of polyomaviruses found in the 
human body continues to grow, raising the question of how many more species have yet to be 
identified and what roles they play in humans with and without manifest disease. 
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INTRODUCTION 
 Over the past five years, seven novel polyomaviruses have been discovered in humans, 
including KI polyomavirus (KIPyV) (1), WU polyomavirus (WUPyV) (2), Merkel cell 
polyomavirus (MCPyV) (3), human polyomavirus 6 (HPyV6) (4), human polyomavirus 7 
(HPyV7) (4), Trichodysplasia spinulosa-associated polyomavirus (TSPyV) (5) and human 
polyomavirus 9 (HPyV9) (6). Polyomaviruses also infect a wide variety of mammalian and avian 
hosts, including the recently described novel polyomaviruses of bats (Myotis species, (7)), sea 
lions (Zalophus californianus (8, 9)), multimammate mice (Mastomys species (10)), canaries 
(Serinus canaria (11)), orangutans (Pongo species (12)), squirrel monkeys (Saimiri species (13)), 
chimpanzees ((Pan troglodytes verus (14)) and gorillas (Gorilla gorilla (14)).   
Viruses in the Polyomaviridae family typically possess ~5,000 base pair (bp) circular, 
double-stranded DNA genomes. The genome can be divided into three parts--the regulatory 
region, the early region and the late region. The regulatory region, also called the noncoding 
control region (NCCR), contains the origin of replication and promoters for the early and late 
regions. Transcription occurs bidirectionally from the regulatory region. The early region is 
expressed from a common primary transcript and is alternatively spliced to produce the large T 
antigen (LTAg) and small T antigen (STAg) prior to viral replication. LTAg and STAg typically 
share the first ~80 amino acids. The late region is expressed after viral replication has begun and 
encodes the structural proteins VP1, VP2 and VP3. VP1, the major structural protein, typically 
comprises over 70% of the viral particle and is the antigenic portion of the virus to which most 
natural antibodies are made (15).   
Disease associations have been established for some of the human polyomaviruses. The 
two well-studied human polyomaviruses BK polyomavirus (BKPyV) and JC polyomavirus 
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(JCPyV) are important human pathogens. BKPyV is known to cause BK nephropathy, which can 
lead to renal allograft failure, and hemorrhagic cystitis, while JCPyV is the etiological agent of 
progressive multifocal leukoencephalopathy (PML). Both viruses are ubiquitous worldwide, with 
seroprevalence rates of 55-85% for BKPyV and 44-77% for JCPyV (16). Following primary 
infection in childhood, BKPyV and JCPyV establish persistent latent infections that can 
periodically reactivate, leading to shedding of infectious virus in the urine (17). Primary 
infection and periodic reactivation are typically asymptomatic unless the host is 
immunocompromised, in which case life-threatening illness can occur (17). MCPyV is 
associated with Merkel cell carcinoma (MCC), a rare but aggressive skin cancer. MCPyV DNA 
is found in ~80% of MCC tumors and is clonally integrated into a subset of these (18). TSPyV 
has been linked to Trichodysplasia spinulosa, a very rare skin condition associated with 
immunosuppression following organ transplantation (19). It is unclear if the other human 
polyomaviruses play a role in disease.   
The recently discovered human polyomaviruses have all been identified through the use 
of molecular methods for detection of viral nucleic acids. WUPyV and KIPyV were discovered 
using high-throughput Sanger sequencing (1, 2). MCPyV was identified using digital 
transcriptome subtraction, which entails pyrosequencing of a cDNA library followed by 
subtraction of human reads to identify novel viral sequences (3). HPyV6 and TSPyV were 
discovered using rolling circle amplification (RCA) (4, 5), and consensus PCR primers were 
utilized to find HPyV7 and HPyV9 (4, 6). 
 We used shotgun pyrosequencing of purified virus-like particles (VLPs) recovered from a 
fecal sample to discover a novel polyomavirus in the stool of a healthy child from Malawi. The 
virus was also detected in 12 additional stool samples from the United States, indicating it has a 
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wide geographic distribution. As stool is not a sterile site, it is currently unknown whether this 
polyomavirus actively infects humans. Finally, we compared the whole genome nucleotide 
sequences of the index Malawi case and a case from St. Louis and found these two strains to 
have 5.3% nucleotide variation. 
 
MATERIALS AND METHODS 
Human studies. This study was approved by the College of Medicine Research and Ethics 
Committee of the University of Malawi and the Human Research Protection Office of 
Washington University in St. Louis. The index stool specimen was obtained from a healthy, 
breast-fed, 15-month-old female living in Mayaka, Malawi, in September 2008 as part of a 
global gut microbiome survey (20).  
A total of 514 stool specimens from St. Louis were tested for MWPyV. Stool samples 
were from children, aged birth to 18 years, with diarrhea and were submitted to the St. Louis 
Children's Hospital, St. Louis, Missouri, microbiology laboratory for bacterial culture from July 
2009 to June 2010.  
Sample preparation and 454 pyrosequencing. VLPs were purified as described earlier (21) 
with minor modifications. In brief, 50mg of a frozen fecal sample was resuspended in 400L of 
SM buffer (100mM NaCl, 8mM MgSO4, 50mM Tris (pH 7.5) and 0.002% gelatin (w/v)). 
Following centrifugation (2,500xg for 10 min at 4ºC) and filtration through 0.45 and 0.22m 
pore-size Millex filters (Millipore) to remove bacterial cells and large particles, the sample was 
treated with chloroform (0.2 volumes) for 10 min and centrifuged for 5 min at 2,500xg. The 
aqueous phase was treated with Baseline-Zero DNase (2.5 U/ml) (Epicentre) for one hour at 
37ºC to remove free DNA, followed by an incubation at 65ºC for 15 min to inactivate the 
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enzyme. To extract VLP-associated DNA, the solution was treated with 10L 10% SDS and 3L 
Proteinase K (20mg/ml) for 20 min at 56ºC. Subsequently, 35L of 5M NaCl and 28L of a 
solution of 10% cetyltrimethylammonium bromide/0.7M NaCl were introduced. After a 10 min 
incubation at 65ºC, an equal volume of chloroform was added, and the mixture was centrifuged 
for 5 min at 8,000xg at room temperature. The supernatant was transferred to a new tube, and an 
equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) was added, followed by 
centrifugation for 5 min at 8,000xg at room temperature. The supernatant was collected, and the 
DNA was purified using Qiagen MiniElute columns following manufacturer instructions, with a 
final elution volume of 35L.  
Purified VLP-derived DNA (1L) was used as input in a 20L RCA reaction using the 
illustra GenomiPhi V2 kit (GE Healthcare) as recommended by the manufacturer (n= four 
independent reactions). After 90 minutes of amplification, the four reactions were pooled and 
purified using the Qiagen DNeasy kit. DNA (500ng) was subjected to 454 FLX Titanium 
pyrosequencing.  
Analysis of pyrosequencing reads. The individual 454 reads were analyzed using a custom 
bioinformatics pipeline as previously described (22). In brief, unique, high quality reads were 
aligned against the reference human genome and the Genbank nt (nucleotide) database using 
BLASTn. Reads with no hits or hits with an E-value greater than e-5 were then aligned using 
BLASTx to the GenBank nr (non-redundant) database, and reads aligning to viral sequences with 
the lowest e value were identified. 
Complete genome sequencing. PCR primers were designed to span the gaps between the six 
reads showing significant similarity to polyomaviruses generated by pyrosequencing to obtain an 
initial whole genome sequence. The sequences for these primers are available upon request. The 
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complete MWPyV genome derived from the index Malawi case (designated strain MA095, 
Genbank JQ898291) was sequenced to greater than 3x coverage using four sets of overlapping 
PCR primers. They were (listed 5’ to 3’) (ES087) ACTTAAACCATGTTCCTGACTCTGT and 
(ES091) ACAGAGATTACAGCACCCATATACT, (ES088) 
GCATCTGCCCTGGTACAAACA and (ES092) CAGACAACTCAGAAGTTTCCACCTC, 
(ES089) GAAGTAGAAGGAGAGGAAAATGCCG and (ES093) 
TGCTGTTGAGGATACACAACAAGAC, and (ES090) 
AGGCTGCTTAAAGGCCTATGAATG and (ES094) CTGAAACACCAGTTGCTCCAGC. 
Amplicons from independent PCR reactions were cloned into pCR4 (Invitrogen) and 
bidirectionally sequenced. The complete genome from St. Louis sample WD976 (Strain WD976, 
Genbank JQ898292) was amplified and sequenced to greater than 3x coverage in the same 
manner, using the same primer pairs.  
Genome annotation. Open reading frames (ORFs) were predicted using NCBI ORF Finder. The 
LTAg and STAg ORFs were manually scanned for conserved splice donor and acceptor sites. 
Conserved motifs in the TAgs and in the NCCR were identified using NCBI CD-Search software 
(23) and by manual identification. Prediction of putative binding sites for transcription factors 
was performed using AliBaba software, version 2.1 (24). The NCCR region was scanned for 
palindrome patterns using the EMBOSS palindrome software (25).  
Phylogenetic analysis. Protein sequences associated with the reference genomes for 27 
polyomaviruses were obtained from GenBank; these included:  baboon polyomavirus 
(NC_007611, SA12) (26), bat polyomavirus (NC_011310, BatPyV) (7), B-lymphotropic 
polyomavirus (NC_004763, LPyV) (27), BKPyV (NC_001538) (28), Bornean orangutan 
polyomavirus (NC_013439, OraV1) (12), bovine polyomavirus (NC_001442, BPyV) (29), 
29 
 
California sea lion polyomavirus (NC_013796, SLPyV) (8), hamster polyomavirus (NC_001663, 
HaPyV) (30), JCPyV (NC_001699) (31), MCPyV (HM011557) (4), murine pneumotropic virus 
(NC_001505, MPtV) (32), murine polyomavirus (NC_001515, MPyV) (33), simian virus 40 
(NC_001669, SV40) (34), Squirrel monkey polyomavirus (NC_009951, SqPyV) (13), Sumatran 
orangutan polyomavirus (FN356901, OraV2) (12), TSPyV (NC_014361) (5), HPyV6 
(NC_014406) (4), HPyV7 (NC_014407) (4), KIPyV (NC_009238) (1), WUPyV (NC_009539) 
(2), avian polyomavirus (NC_004764, APyV) (35), canary polyomavirus (GU345044, CaPyV) 
(11), crow polyomavirus (NC_007922, CPyV) (36), finch polyomavirus (NC_007923, FPyV) 
(36), goose hemorrhagic polyomavirus (NC_004800, GHV) (37), chimpanzee polyomavirus 
(NC_014743, ChPyV) (38) and HPyV9 (NC_015150) (6). The predicted open reading frames for 
MWPyV LTAg, VP1 and VP2 were aligned with the corresponding proteins from the 27 known 
polyomaviruses using Fast Statistical Alignment (FSA) software, version 1.15.2 (39). For the 
LTAg analysis, unalignable regions were removed, and the remainder of the alignment was 
concatenated. Maximum likelihood trees were generated using PhyML, version 3.0 (40), with 
1,000 bootstrap replicates and the best model as determined by Prot Test software, version 2.4 
(41); these were RtRev for VP1 and LG for VP2 and LTAg. 
Nucleic acid extraction. Stools which had been frozen at -80°C were diluted approximately 1:6 
in PBS and filtered through 0.45 m membranes prior to extraction. Total nucleic acids were 
extracted using an Ampliprep Cobas automated extractor (Roche) and eluted in a volume of 
75L. The samples were arrayed in a 96-well plate for storage at -80°C. 
Real-time PCR screening of the St. Louis cohort. A Taqman real-time PCR assay was 
designed to target the MWPyV LTAg using Primer Express software (Applied Biosystems). 
Primers and probe used for this assay were (ES105) 5'-TGAGAAGGCCCCGGTTCT-3', 
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(ES106) 5'- GAGGATGGGATGAAGATTTAAGTTG-3' and (ES107) 5'-FAM-
CCTCATCACTGGGAGC-MGBNFQ-3'. The resulting amplicon was 73bp. Standard curves 
were generated using serial 10-fold dilutions ranging from 5 x 10
6
 to 5 copies of a positive 
control plasmid (plasmid K-p31) per reaction. The 25L PCR reactions consisted of 5l of 
extracted sample, 1x universal TaqMan® real-time PCR master mix (Applied Biosystems), 12.5 
pmol of each primer and 4 pmol of the probe. Samples were tested in 96-well plate format, with 
eight water negative controls (one per row) and one positive control containing 50 copies of 
plasmid per plate. The cycling conditions were: 50°C for 2 min, 95°C for 10 min and 45 cycles 
of 95°C for 15 sec followed by 60°C for 1 min. Reactions were run on an ABI 7500 real-time 
thermocycler (Applied Biosystems). The threshold of all plates was set at a standard value, and 
the data was analyzed using the ABI software. Samples were counted as positive if their Ct was 
<35. 
Viral genome accession numbers. The sequences reported here were deposited in GenBank 
under the accession numbers JQ898291 (Index case, strain MA095) and JQ898292 (St. Louis 
case, strain WD976). 
 
RESULTS 
Discovery of a novel polyomavirus by pyrosequencing. MW polyomavirus was 
discovered in a stool sample from a child from Malawi that was collected in September 2008 as 
part of a global gut microbiome survey project (20). Following purification of VLPs by passage 
through 0.45 and 0.22m pore-sized filters and subsequent DNase treatment, DNA was extracted 
from the VLPs and amplified using the highly processive phi29 polymerase. The resulting 
material was subjected to 454 pyrosequencing. Six reads were identified with limited similarity 
31 
 
to known polyomaviruses. Three of the initial six reads could be assembled into one 959 bp 
contig with the highest scoring BLASTx hit possessing 36% amino acid identity to LPyV STAg. 
The other three reads all aligned to the VP1 protein of known polyomaviruses by BLASTx and 
shared 64%, 48% and 59% amino acid identity to JCPyV VP1, TSPyV VP1 and JCPyV VP1.  
Complete genome sequencing and genome analysis. A series of PCR primers were 
designed based on the initial six reads. Sequencing of the resulting amplicons yielded a complete 
genome of 4,927 bp (Figure 2.1). ICTV has set the demarcation criteria for proposed new 
polyomaviruses at 81% nucleotide identity over the whole genome (42). Based on the limited 
sequence similarity to any known polyomaviruses, we named the novel virus MW polyomavirus 
(MWPyV) after its discovery in Malawi. The overall GC content of MWPyV was 37%, which is 
very similar to WUPyV (39%), BKPyV (39%) and JCPyV (40%). The MWPyV genome 
organization was characteristic of the known polyomaviruses and included an early region 
coding on one strand for LTAg and STAg and a late region coding on the opposite strand for the 
structural proteins VP1, VP2 and VP3. The sizes of the predicted ORFs were comparable to 
those of known polyomaviruses (Table 2.1).  
 
Figure 2.1. Genome organization of MWPyV. ori, origin of replication. 
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Table 2.1. Putative proteins encoded by MWPyV (strain MA095) 
Protein 
Putative 
coding region(s) 
Predicted 
size (aa) 
Calculated 
mass (kDa) 
Range (aa) in other 
polyomaviruses 
STAg 4927-4328 199 23.4 124-198 amino acids 
LTAg 
4927-4688, 
4332-2566 
668 77.0 599-817 amino acids 
VP1 1353-2564 403 43.6 343-497 amino acids 
VP2 431-1363 310 34.2 241-415 amino acids 
VP3 761-1363 200 22.8 190-272 amino acids 
 
The TAgs and VP2 were separated by a regulatory region, which had an A/T-rich tract on 
the late side of the putative replication origin. The core origin of replication contained three 
repeats of the consensus pentanucleotide LTAg binding site, G(A/G)GGC (43) (two GAGGC 
and one GGGGC), and one non-consensus binding site, TAGGC. Several polyomaviruses 
(BKPyV, JCPyV, WUPyV, KIPyV and SV40) contain an imperfect palindrome sequence 
followed by additional LTAg binding sites to the early side of the four binding sites. Palindrome 
patterns were identified in MWPyV but no additional LTAg binding sites were detected in this 
area. The regulatory region contained several predicted transcription factor binding sites, 
including multiple binding sites for four factors known to play a role in BKPyV viral 
transcription and regulation--Sp1, nuclear factor I (NFI), AP1 and C/EBP (44). Multiple binding 
sites were also identified for HNF-3, USF-2 and Oct-1. Many other transcription factors were 
predicted to bind to only one site.  
 Analysis of the MWPyV LTAg ORF revealed a conserved splice donor site immediately 
after amino acid 80; the position of this site was similar to that found in WUPyV, BKPyV and 
JCPyV, which occur after amino acids 84, 81 and 81, respectively. Two consensus splice 
acceptor sites were identified, which would yield introns of 355 or 463 bp and proteins of 668 or 
632 amino acids, respectively. Examination of the protein sequence of the 632 amino acid form 
showed that it lacked the Rb-binding motif, which was contained in the excised intron. By 
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contrast, the predicted 668 amino acid protein included the conserved Rb-binding motif. Based 
on this analysis, we predicted the LTAg to be 668 amino acids. 
 MWPyV LTAg possessed conserved features common to other polyomavirus LTAgs, 
including a DNaJ domain containing the conserved region 1 (cr1) sequence and the highly 
conserved hexapeptide motif HPDKGG. These domains were followed by conserved region 2 
(cr2), which contained the Rb-binding motif LxCxE (LSCNE in MWPyV), a putative nuclear 
localization signal (NLS), a canonical DNA binding domain and a zinc finger region. Closer 
inspection of the zinc finger region revealed a conserved C2H2 zinc finger motif with the 
sequence C324, C327, H334, H339. There are typically three highly conserved amino acids N-
terminal to the first cysteine (C324) in this motif, including a tyrosine 10 amino acids away, an 
aspartic acid located 18 amino acids away and an alanine present 25 amino acids away (43). In 
MWPyV, the aspartic acid and alanine residues were conserved, while the tyrosine was not and 
was replaced by a leucine. A conserved leucine-rich hydrophobic region C-terminal to the 
aspartic acid was also present. Following the zinc finger region, the MWPyV LTAg contained 
the highly conserved ATPase-p53 binding domain, including the two conserved motifs 
GPXXXGKT and GXXXVNLE. There was no sequence corresponding to the host range domain 
present in SV40, BKPyV, SA12 and JCPyV (43).  
 In most polyomaviruses, STAg is encoded by a single unspliced ORF. In HaPyV and 
MPyV, the STAg transcript is spliced. Analysis of the MWPyV early region did not reveal an 
obvious splice donor site, so the STAg was predicted to be 199 amino acids. As LTAg and STAg 
share the first 80 amino acids, the STAg also contained the DNaJ domain. In the unique C-
terminal part of STAg, there was a conserved cysteine-rich motif, CX5CX7-8CXCX2CX21-
22CSCX2CX3WFG. This motif was conserved in MWPyV with the exception of the initial 
34 
 
cysteine residue and the serine residue, which were an isoleucine and a phenylalanine, 
respectively. 
 MPyV and HaPyV encode a middle T antigen (MTAg) generated by alternative splicing; 
the MWPyV genome was scanned for splicing motifs similar to those used by MPyV and 
HaPyV. No obvious splice sites that would generate an appropriately sized third T antigen 
protein were identified, suggesting that MWPyV likely does not encode a MTAg. 
 Some polyomaviruses, including JCPyV and BKPyV, also encode an agnoprotein in the 
late region between the NCCR and the VP2 start codon. Analysis of the MWPyV sequence in 
this region yielded one 45 amino acid ORF on the same strand as the structural proteins. 
However, because this ORF was not conserved in the other completely sequenced MWPyV 
strain, strain WD976 (described later in this report), we do not believe that MWPyV encodes an 
agnoprotein. 
Phylogenetic analysis. Maximum likelihood analysis of the VP1, VP2 and LTAg 
proteins demonstrated MWPyV was highly divergent from all known polyomaviruses (Figure 
2.2). Analysis of VP1 sequences showed that MWPyV is midway between the 
Wukipolyomavirus and Orthopolyomavirus genera (Figure 2.2A). By contrast, based on VP2 and 
LTAg sequences, MWPyV clustered with the clade containing HPyV9, LPyV, HaPyV, MPyV, 
TSPyV, MCV, ChPyV and the orangutan polyomaviruses (Figure 2.2B and 2.2C). The 
discordant phylogenetic relationships suggest that MWPyV might have been derived from an 
ancestral recombination event.  
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Figure 2.2. Phylogenetic analysis of MWPyV. Amino acid-based trees were generated using the 
maximum likelihood method with 1,000 bootstrap replicates. Bootstrap values less than 700 are 
not shown. A) VP1; B) VP2; C) LTAg. 
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Prevalence of MWPyV. A Taqman real-time PCR assay targeting the MWPyV LTAg 
was designed and validated using a positive control plasmid; based on the standard curve, the 
MWPyV assay demonstrated a reliable detection limit of approximately five copies per reaction, 
yielded a linear regression R
2
 value of 0.99 and was 93% efficient. This real-time PCR assay was 
used to screen a cohort consisting of 514 stool samples from children at St. Louis Children's 
Hospital presenting with diarrhea. Twelve samples (2.3%) from the St. Louis cohort tested 
positive for MWPyV (Table 2.2).  
 
Table 2.2. Specimens and patients testing positive for MWPyV 
Sample Patient Age Sex Ct Date Tested positive Tested negative 
WD972 1 5y 0m M 21.68 8/10/09 E. coli serotype O Rough 
 
Enteric pathogen culture* (except E. coli), 
Giardea, Cryptosporidium, Ova & parasite 
screen (O&P) 
WD976 1   21.85 8/11/09 E. coli serotype O Rough 
Enteric pathogen culture* (except E. coli), 
Giardea, Cryptosporidium, C. difficile, O&P 
WD1226 1   28.21 12/22/09  Enteric pathogen culture*, O&P 
WD1239 2 1y 0m M 31.76 12/29/09  Enteric pathogen culture*, C. difficile 
WD1314 3 1y 5m F 30.37 2/11/10  Enteric pathogen culture*, Rotavirus 
WD1300 4 1y 8m F 34.99 2/4/10  
Enteric pathogen culture*, Rotavirus, Viral 
culture 
WD1260 5 1y 4m F 29.91 1/12/10  Enteric pathogen culture*, O&P 
WD958 6 1y 8m M 31.89 8/3/09  Enteric pathogen culture*, C. difficile, O&P 
WD1039 7 4y 3m F 31.42 9/14/09  Enteric pathogen culture*, C. difficile 
WD1233 8 4y 9m M 32.33 12/25/09  Enteric pathogen culture*, Rotavirus 
WD1055 9 5y 5m M 30.90 9/22/09  Enteric pathogen culture* 
WD1442 10 3y 0m M 32.41 5/24/10 C. jejuni Enteric pathogen culture* (except C. jejuni). 
*Includes Salmonella, Shigella, E. coli O157, E. coli shiga toxins not 0157, Yersinia, Aeromonas, Plesiomonas and Campylobacter. 
 
Three of the MWPyV positive samples were obtained from a five-year-old lung transplant 
recipient over a period of four months from August to December 2009 (Patient 1, Table 2.2). 
This patient had received a lung transplant three years earlier and at the time of sampling 
presented with persistent, recurrent diarrhea. Two of the samples, WD972 and WD976, were 
obtained on consecutive days in August 2009, and both samples were positive for Escherichia 
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coli serotype O Rough. The patient again presented with diarrhea in December 2009 (sample 
WD1226), but this sample had no growth in the enteric pathogen culture (including E. coli) and 
was negative for ova and parasites (Table 2.2). The other nine samples came from nine 
individual patients ranging in age from one to five-years-old (Table 2.2). Eight of the nine 
patients were negative for all organisms tested except MWPyV. Only patient 10 (sample 
WD1442) was positive for Campylobacter jejuni.   
Strain variation. To assess the extent of sequence variation between the St. Louis and 
Malawi isolates, we sequenced the complete genome of MWPyV from St. Louis sample WD976 
to greater than 3x coverage. The two whole genome sequences diverged by 5.3% at the 
nucleotide level. Strain WD976 had two insertions (11 bp and one bp) in the NCCR, which 
resulted in a genome size of 4,939 bp. The vast majority of the polymorphisms in the coding 
regions resulted in synonymous mutations. One notable mutation changed the size of the STAg 
ORF. The predicted TAA stop codon identified in the MA095 strain was mutated to AAA in 
WD976 resulting in a protein prediction of 206 amino acids, seven amino acids longer than the 
index genome's STAg. 
  
DISCUSSION 
 We used a pyrosequencing strategy to identify a novel polyomavirus present in human 
stool. The initial discovery was in a stool specimen collected from a healthy child in Malawi. 
Further screening by real-time PCR demonstrated the presence of the virus in 12 stool samples 
collected from a cohort of patients in St. Louis, USA. These data demonstrated that MWPyV is 
geographically widespread in human populations and can be found on two continents. As the 
ICTV polyomavirus subgroup currently has no systematic naming convention for novel 
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polyomaviruses, we chose to name this new virus using a two letter convention following the 
model of BKPyV, JCPyV, KIPyV and WUPyV; we made this decision for two reasons. First, we 
did not employ the numerical system used in the naming of HPyV6, HPyV7 and HPyV9 because 
we have not yet formally demonstrated that this virus infects humans and to avoid potential 
conflicts in temporal priority in describing novel polyomaviruses. Second, both MCPyV and 
TSPyV are named based on putative disease associations, but no disease association currently 
exists for our new virus. Therefore, we chose a two-letter abbreviation reflecting the geographic 
location of the index case.   
 The ICTV polyomavirus subgroup recently defined two mammalian genera, 
Orthopolyomavirus and Wukipolyomavirus, within the family Polyomaviridae based primarily 
on phylogenetic analysis of the late genes (combined VP1 and VP2) (42). Classification of 
MWPyV into one of these two genera is confounded by the distinct phylogenetic tree topologies 
that were generated for the VP1 and VP2 proteins (Figure 2.2). The different topologies suggest 
that MWPyV is derived from an ancestral recombination event. Such recombination among 
polyomaviruses has been previously suggested (4). 
 We sequenced two complete genomes of MWPyV, one from the index child in Malawi 
and one from a child in St. Louis. A high degree of strain variation (5.3%) was observed between 
these two MWPyV strains, which is comparable to the ~ 5% sequence divergence present in 
strains of BKPyV (45). It contrasts sharply with the very limited variation (<1.2%) seen with 
WUPyV worldwide (46). The primers and probe used in the aforementioned MWPyV real-time 
PCR assay were perfectly conserved in both strains and thus detect both stains with equal 
efficiency. However, it remains to be determined whether even greater variation in MWPyV can 
be discovered when broader consensus sequence-based assays are used. Others have speculated 
39 
 
that sequence variation in BKPyV and JCPyV plays a role in viral pathogenesis and disease 
severity (47, 48). If MWPyV is ultimately found to be a pathogen, it will be interesting to 
determine whether there are strain-dependent pathogenic phenotypes. Among the differences we 
observed were a seven amino acid extension of the STAg and an 11 bp insertion in the NCCR in 
the WD976 strain versus the index Malawi strain. The functional consequences of these 
alterations remain to be defined. 
 One critical question is whether MWPyV is a bona fide infectious agent of humans and if 
so, what disease(s), if any, might be associated with MWPyV infection. The detection of 
MWPyV in stools of children with diarrhea, many of which have no known etiology, raises the 
possibility that MWPyV might play a role in human diarrhea. Alternatively, it is possible that 
MWPyV does not cause infection in the gastrointestinal tract but has a tropism for other human 
organ systems and is shed in stool as a mode of transmission or simply as a byproduct. It is also 
possible that MWPyV is a dietary contaminant and does not actively infect humans. Approaches 
to determine whether MWPyV is an infectious agent include serological studies to determine 
whether the host mounts an antibody-based immune response to MWPyV and additional 
screening of specimens collected from sterile sites, such as serum or cerebrospinal fluid. Further 
studies will be needed to define whether MWPyV has additional tropisms in the human body and 
to assess potential associations with human disease.  
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ABSTRACT 
WU polyomavirus (WUPyV) and KI polyomavirus (KIPyV) were both discovered in 2007 in 
respiratory tract secretions from patients with respiratory illness. Serological analysis 
demonstrated that both infect a majority of the population, and their DNA can be detected in a 
variety of specimen types. Little is known about the tissue tropism of WUPyV and KIPyV, and 
there are no studies to date describing any specific cell types they infect. The limited knowledge 
of their tropism has hindered study of these viruses and an understanding of their potential 
pathogenesis in humans. We describe tissues from five immunocompromised patients that 
stained positive for WUPyV or KIPyV antigen using newly developed immunohistochemical 
assays targeting either the WUPyV VP1 (WU-VP1) or KIPyV VP1 (KI-VP1) capsid protein. 
WU-VP1 and KI-VP1 were both detected in lungs within alveolar macrophages. WU-VP1 was 
also detected in bronchial epithelial cells from a bronchoalveolar lavage specimen and in close 
association with MUC5AC (a mucin)-positive cells in tracheal tissue. In addition, KI-VP1 was 
detected in splenic tissue. Two of the patients died of respiratory-related issues. In one of these 
cases, subsequent studies revealed polyomavirus-like particles in the patient’s lung. This is the 
first definitive identification of specific cell types in which WU-VP1 or KI-VP1 can be detected 
and the first demonstration of putative WUPyV viral particles in a human.  Collectively, these 
findings further our understanding of WUPyV and KIPyV biology and tropism and raise the 
question of whether these viruses cause disease, particularly in the immunocompromised.  
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INTRODUCTION 
WU polyomavirus (WUPyV) and KI polyomavirus (KIPyV) were discovered in 2007 in 
patients with respiratory tract infections (1, 2). Subsequent studies detected both viruses in 
respiratory tract secretions, blood, stool and tonsil tissue (3) and suggested a seroprevalence of 
55-70% (4, 5) for KIPyV and 69-89% for WUPyV (4-6), with infection occurring most 
frequently in childhood. Neither is currently associated with any human disease(s). However, 
other polyomaviruses are known to be important human pathogens. JC polyomavirus (JCPyV) is 
the etiological agent of progressive multifocal leukoencephalopathy, and BK polyomavirus 
(BKPyV) can lead to renal allograft loss in kidney transplant recipients and hemorrhagic cystitis 
in bone marrow transplant recipients. Both viruses are ubiquitous worldwide (7). Despite their 
high prevalence rates, infection by both viruses is typically asymptomatic unless the host is 
immunocompromised (7). More recently, Merkel cell carcinoma polyomavirus (MCPyV) and 
Trichodysplasia spinulosa-associated polyomavirus (TSPyV) were implicated as human 
pathogens in the context of immunosuppression (8, 9). MCPyV causes Merkel cell carcinoma, a 
rare but aggressive skin cancer (9), and TSPyV is associated with Trichodysplasia spinulosa, a 
rare skin disease seen in transplant recipients (8). Given the pathogenicity of these family 
members, a significant question is whether WUPyV and KIPyV follow this paradigm and cause 
disease in immunocompromised patients.  
A complete understanding of the types of cells and tissues in which WUPyV and KIPyV 
replicate is critical to identifying potential diseases with which they may be associated. The 
viruses have most commonly been detected in respiratory secretions, but there have been only 
minimal efforts to explore additional specimen types. In addition, prior studies relied exclusively 
on PCR approaches to detect viral genomes in bulk-extracted nucleic acid, making it impossible 
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to define the specific cell type(s) that harbor WUPyV or KIPyV. There are no published reports 
describing the detection of viral antigens in tissues. In order to define the tissue and cell tropism 
of WUPyV and KIPyV and as a step toward understanding the roles of the viruses in human 
disease, we developed immunohistochemical (IHC) assays targeting either WUPyV or KIPyV 
VP1 (WU-VP1 or KI-VP1), the viral capsid proteins.  
We applied this assay to tissue specimens from patients positive for WUPyV or KIPyV 
by PCR. Tissues from five different patients were positive. KI-VP1 was detected in the lung 
tissue of a deceased pediatric bone marrow transplant recipient, and a portion of the positive cells 
was identified as alveolar macrophages using a double immunohistochemical stain. In addition, 
KI-VP1 was detected in the spleen and lung tissues of a deceased HIV-positive patient. WU-VP1 
was detected in respiratory epithelial cells from a bronchoalveolar lavage sample from a bilateral 
lung transplant recipient with Job’s syndrome. WU-VP1 was also detected within alveolar 
macrophages in the lung of a deceased patient with viral pneumonitis and in the lung of another 
patient. These results provide the first insights into a specific cell types in which WUPyV or 
KIPyV can be detected.   
 
MATERIALS AND METHODS 
Development of anti-WU-VP1 and anti-KI-VP1 monoclonal antibodies. The methods used to 
develop anti-WU-VP1 and anti-KI-VP1 monoclonal antibodies were identical and performed in 
parallel. The WU-VP1 and KI-VP1 Gateway pENTR/SD/D-TOPO constructs previously 
described (4) were transferred into Gateway pDEST17 plasmids (Life Technologies) and 
expressed in E. coli. The resulting recombinant His-tagged VP1 proteins were purified via 
affinity Ni-NTA columns (Pierce Biotechnology). BALB/c mice were immunized with three 
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consecutive doses of either purified WU-VP1 or KI-VP1. Their spleens were harvested for 
hybridoma fusion with the murine myeloma line P3X63Ag8.653 (Sigma-Aldrich). We screened 
for clones producing anti-KI-VP1 or anti-WU-VP1 antibody by ELISA and Western blot using 
purified GST-tagged WU-VP1 or KI-VP1 as the target antigen. Positive clones were then 
screened by ELISA using the reciprocal GST-tagged antigen (4), and those demonstrating cross 
reactivity were excluded. For example, a clone producing anti-KI-VP1 antibody was screened 
using GST-WU-VP1 to determine if it cross-reacted. Two rounds of limiting dilutions were 
performed to achieve clonality. Both monoclonal antibodies used in the following experiments, 
NN-Ab03 for KI-VP1 and NN-Ab06 for WU-VP1, were isotype IgG2b.   
Generation of positive controls. We generated positive controls for the two 
immunohistochemistry assays by transfecting 293T cells with a plasmid (pDEST26, Life 
Technologies) encoding either WU-VP1 or KI-VP1. Cells were harvested three days after 
transfection, and a portion was fixed in 10% neutral buffered formalin for 24 hours, embedded in 
paraffin, and sections of the cell block were transferred to glass slides.  
Immunohistochemistry (IHC). Two slightly different IHC assay were used. The primary assay 
was as follows. Formalin-fixed paraffin-embedded tissue sections were deparaffinized in xylene 
for 15 minutes and then rehydrated in a series of graded ethanol solutions. Endogenous 
peroxidases were quenched in 3% hydrogen peroxide for 15 minutes. Antigen retrieval was 
accomplished in citrate buffer pH 6.0 (10mM citric acid, 0.05% Tween 20) in a pre-warmed 
pressure cooker (Nesco PC6-25) for three minutes on the high setting. After blocking in 1.5% 
normal horse serum (Vector Labs #S-200), the tissues were incubated first in primary antibody 
overnight and then in secondary antibody (biotinylated anti-mouse IgG, Vector BA-2000) for 30 
minutes. Primary antibodies included monoclonal antibodies against WU-VP1 (designated NN-
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Ab06), KI-VP1 (NN-Ab03) or an isotype matched control antibody (mouse IgG2b, BD 
Biosciences #557351). The staining was developed using the Vectastain standard ABC kit 
(Vector Labs #PK-6100) and DAB (Vector Labs #SK-4100), counterstained with hematoxylin 
and dehydrated in a series of graded ethanol solutions and xylene. 
 For the HIV-positive cases (#3 and 5), a second IHC assay was used. Tissue sections 
were deparaffinized in three changes of xylene and then rehydrated in a series of graded ethanol 
solutions. Antigen retrieval was accomplished in citrate buffer at 95
°
C in a water bath for 35 
minutes. Slides were then stained using the Histostain®-Plus 3
rd
 Generation IHC Detection kit 
(Life Technologies) according to the manufacturer’s instructions, with Superblock T20 (Thermo 
#37516) used as the blocking agent. NN-Ab03 or the isotype control was used as the primary 
antibody. After completion of the Histostain protocol, the slides were counterstained with 
hematoxylin and dehydrated in a series of graded ethanol solutions and xylene.  
Double immunohistochemistry (dIHC). The dIHC staining protocol was similar to the primary 
IHC protocol with the addition of several steps. Following chromagen development of the first 
antibody using either DAB or ImmPACT SG (Vector Labs #SK-4705), tissues were blocked 
with avidin and biotin (Vector Labs #SP-2001) and a second time with 1.5% normal horse 
serum. They were incubated with the second primary and secondary antibodies and developed 
using the ABC kit and DAB or ImmPACT SG, followed by dehydration. Tissues stained with 
the dIHC protocol were not counterstained. Other primary monoclonal antibodies used were 
against MUC5AC (Thermo Fischer #MA1-38223), CD45 (BD Biosciences #555480), CD45 
(Dako # M351529-2, only used for dIF), CD68 (Dako #M081401), CD31 (Dako #M0823) and 
an isotype matched antibody to these (IgG1, BD Pharmingen #555746). Citrate buffer was used 
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for antigen retrieval in the dIHC assays for MUC5AC, CD45 and CD68, while Tris-EDTA 
buffer pH 9.0 (10mM Tris, 1mM EDTA, 0.05% Tween 20) was used for the CD31 dIHC assay. 
Immunofluorescence (IF) and double immunofluorescence (dIF). Formalin-fixed paraffin-
embedded tissue sections were deparaffinized in xylene for 15 minutes and then rehydrated in a 
series of graded ethanol solutions. Antigen retrieval was accomplished in citrate buffer in a pre-
warmed pressure cooker for three minutes on the high setting. Sections were blocked in 
Superblock T20. A polyclonal antibody against WU-VP1 (4), designated NN-Ab01, was used as 
the primary antibody. Following incubation with the fluorescently labeled secondary antibody 
(anti-mouse-488, Life Technologies #A11001), the nucleus was counterstained with Hoechst 
(Life Technologies #H21491), and the slides were mounted.  
The dIF assay was accomplished in the same way, except two primary antibodies, NN-
Ab01 and a monoclonal antibody against cytokeratins (Dako #M3515) were applied 
simultaneously, followed by two secondary antibodies (anti-rabbit-568 and anti-mouse-488, Life 
Technologies #A10042 and A11001, respectively).  
Nucleic acid extraction and real-time PCR (case #1). DNA was extracted from formalin-fixed 
paraffin-embedded samples using the Qiagen BioRobot M48 workstation and MagAttract DNA 
mini kit (Qiagen, Valencia, CA). A real-time PCR assay designed to detect both WUPyV and 
KIPyV was used to screen 5 uL of a 1:100 dilution of extracted DNA. Extracts were also tested 
for bocavirus using a previously described assay (10). 
Complete genome sequencing (case #1). Segments of the WUPyV genome were amplified 
using a series of primers that are available upon request. Amplicons were cloned and sequenced 
using the ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit version 1.1 or 
3.1 on an ABI 3130 XL DNA Sequencer (Applied Biosystems).  
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Accession numbers. The complete genome sequence for WUPyV isolate Rochester-7029 is 
available through GenBank under Accession #FJ794068.  The genome sequence for WUPyV 
isolate J1 is under Accession #KJ643309. 
Electron microscopy (case #1). Tissues were fixed in formalin following autopsy. They were 
post-fixed in glutaraldehyde before processing into epoxy resin for sectioning.  
Image manipulation. IHC images were cropped to squares. The resolution was changed to 500-
600 dpi in Photoshop with constrained proportions and no resampling. No other image 
manipulation was conducted for IHC images. IF images were also cropped to squares, and the 
resolution was changed in Photoshop. The brightness and contrast was also changed, but these 
changes were applied equally to the entire image.  
Human studies. Studies performed with tissues from all cases except #2 and 4 were performed 
after the patients were deceased, so no institutional review board approval was sought. Studies 
on tissue from case #2 were approved by institutional review boards at the National Institutes of 
Health and Washington University in St. Louis. Studies on tissue from case #4 were approved by 
the Human Research Protection Office of Washington University in St. Louis.  
 
RESULTS 
 Establishment of WU-VP1 and KI-VP1 specific immunohistochemistry assays. To 
study the cell and tissue tropisms of WUPyV and KIPyV, we established IHC assays using 
newly developed monoclonal antibodies against WU-VP1 and KI-VP1. To validate the new IHC 
assays and evaluate their specificity, we developed positive control cell pellets. Figure 3.1a 
shows 293T cells transfected with the pDEST26-KI-VP1 construct and stained with the KI-VP1 
antibody (NN-Ab03). Several cells showed prominent dark staining (Figure 3.1a, b), while cells 
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from both a sequentially cut slide stained with the isotype control (Figure 3.1c) or mock 
transfected 293T cells stained with NN-Ab03 (Figure 3.1d) did not. To independently evaluate 
the specificity of NN-Ab03, a subset of the transfected cells were lysed to extract proteins for 
Western blot analysis (Figure 3.1e). As negative controls, lysates of 293T cells from a mock 
transfection and from a transfection of an analogous plasmid expressing the VP1 protein of WU 
polyomavirus (pDEST26-WU-VP1) were included. A single band corresponding to the predicted 
size of KI-VP1 was detected in the KI-VP1 lysate, while no band is seen in mock transfected 
cells or in the WU-VP1 lysate (Figure 3.1e). The blot was stripped and blotted for actin 
(Millipore #MAB1501) as a loading control.  
Similar control experiments were performed using the anti-WU-VP1 monoclonal 
antibody (NN-Ab06). Cells with prominent dark staining were seen (Figure 3.2a). A serial 
section of the same cell block stained with an IgG2b isotype matched antibody (Figure 3.2b) and 
mock transfected cells stained with NN-Ab06 (Figure 3.2c) were negative. In the Western blot 
using NN-Ab06 (Figure 3.2d), a single band of the size corresponding to WU-VP1 was seen, 
while no band was seen in lysate from an analogous pDEST26-KI-VP1 transfection or in lysate 
from a mock transfection (Figure 3.2d). Given these data, we concluded both antibodies are 
specific for their respective virus, and the assays can detect viral antigen in formalin-fixed 
paraffin-embedded cell pellets. 
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Figure 3.1. Validation of anti-KI-VP1 monoclonal antibody specificity. IHC of 293T cells 
transfected with pDEST26-KI-VP1 and stained with (A, B) a KI-VP1 monoclonal antibody (NN-
Ab03) or with (C) an isotype control. (D) IHC of mock transfected 293T cells stained with NN-
Ab03. Panels A and C are at 400x; panel B is at 600x, and panel D is at 200x. (E) Western blot 
using NN-Ab03 of protein lysates from mock transfected 293T cells (lane 1) or cells transfected 
with pDEST26-KI-VP1 (lane 2) or pDEST26-WU-VP1 (lane 3). 
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Figure 3.2. Validation of anti-WU-VP1 monoclonal antibody specificity. IHC of 293T cells 
transfected with pDEST26-WU-VP1 and stained with (A) a WU-VP1 monoclonal antibody 
(NN-Ab06) or (B) an isotype control. (C) IHC of mock transfected 293T cells stained with NN-
Ab06. Figures A-C are at 400x. (D) Western blot using NN-Ab06 of protein lysates from mock 
transfected 293T cells (lane 1) or cells transfected with pDEST26-WU-VP1 (lane 2) or 
pDEST26-KI-VP1 (lane 3).  
 
 
Case #1:  Multi-organ WUPyV infection in a bone marrow transplant recipient 
detected by electron microscopy, PCR and immunohistochemistry. In January 2001, a 27 
month-old child was admitted to the University of Rochester Medical Center for an unrelated 5/6 
HLA-matched cord blood transplant. The patient was previously diagnosed with refractory 
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juvenile myelomonocytic leukemia at 16 month of age and underwent splenectomy in September 
2000. The patient was born at 40 weeks gestation by normal vaginal delivery. Her medical 
history included leukocytosis at three months old and splenomegaly at six months old. She had 
multiple infections before two years of age, including otitis media, a central vein catheter 
infection and a urinary tract infection. She also demonstrated failure to thrive, was 
developmentally delayed and had mild pulmonic stenosis and gastroesophageal reflux.  
Three weeks after transplant the patient developed fever, diarrhea, hepatomegaly and 
erythema on her face, palm and sole. Her hemodynamics was stable, and she weighed 10 kg. The 
patient was evaluated for graft versus host disease (GVHD), viral exanthema and drug eruption. 
Skin biopsies performed at four weeks post-transplant showed pathologic characteristics 
consistent with viral infection, not GVHD or drug eruption. A rectosigmoid biopsy done at the 
same time showed mild stromal edema but was negative for adenovirus and cytomegalovirus 
(CMV) by IHC stains. Throughout the course of hospitalization, adenovirus was intermittently 
isolated from the patient’s stool and urine, while Influenza B was detected in her nose and throat. 
PCR testing of the blood for CMV was consistently negative. Despite aggressive therapy, the 
patient’s condition continued to deteriorate. On March 1, 2001, the patient was transferred to the 
pediatric intensive care unit (PICU) secondary to respiratory failure. Her chest radiogram was 
remarkable for pulmonary edema. She was stabilized two days later. The patient again developed 
severe acute respiratory distress syndrome and distended abdomen on April 1. Her treatment was 
continued in the PICU and included mechanical ventilation. A radiogram on April 15 (about 11 
weeks post-transplant) revealed free air in the abdominal cavity without identification of the 
source. The patient expired later that day. Viral pneumonitis was indicated as the probable cause 
of death. 
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 The most important findings on gross examination at autopsy were bilateral pulmonary 
consolidation, acute tracheobronchitis, hepatomegaly with cholestasis, deep mucosal ulcerations 
throughout the small bowel and prominent generalized lymphadenopathy. The most notable 
pathologic finding was heavy hemorrhagic foci in the lungs. Microscopic examination of the 
lungs confirmed the presence of interstitial emphysema with profound hemorrhage of the right 
upper, right middle, left upper and left lower lobes. Multiple smudge cells and cells with Cowdry 
type A-nuclear inclusions were identified inside of reactive bronchial epithelium from both 
lungs. Similar inclusions were seen in the tracheal, bile duct, renal tubular and the urinary 
bladder epithelia. Small bowel mucosa revealed multifocal ulcerations and scattered inclusion 
bearing cells in the epithelium. Immunoperoxidase stains for CMV, adenovirus, influenza virus, 
human papillomavirus, respiratory syncytial virus (RSV), SV40 and in situ hybridization for 
Epstein barr virus were all negative. Attempts to culture virus from the lung, liver, 
gastrointestinal tract and lymph node tissues were unsuccessful. Gram stains from sections of 
lung, liver and lymph node showed greater than 25 neutrophils per low field with no organism 
seen. Staphylococcus species coagulase negative grew from a blood culture (at 10 CFU/mL) and 
from the gastrointestinal tract. No strict anaerobic growth was observed. 
Interestingly, electron micrographs of the lungs showed spherical viral particles in the 
nuclei, many with para-crystalline arrays (Figure 3.3). The particles were 30.39-34.71 nm (mean 
32.11 nm) in diameter. Although the diameter was less than the conventional diameter for 
polyomaviruses (45 nm), shrinkage due to formalin fixation is a well-established phenomenon, 
and the size of viral particles can vary based on the method of fixation and embedding (11). In 
addition, previously published electron microscopy on BKPyV particles yielded measurements 
ranging 30-50 nm (12). Despite the presence of viral particles indicative of polyomavirus, IHC 
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on lung tissue with a primary antibody against SV40 known to cross-react with BKPyV and 
JCPyV was negative. IHC for adenovirus and RSV was also negative. Although electron 
microscopy indicated a likely viral infection in the lungs, given the negative IHC, no further 
testing was performed at that time. 
 
Figure 3.3. Electron micrographs of polyomavirus-like particles in a human lung. (A-C) Various 
fields of human lung demonstrating viral particles. Crystalline lattices seen in panel B are 
consistent with polyomavirus virions.  
 
 
Detection of WUPyV in the lung. Two new polyomavirus, WUPyV and KIPyV, were 
discovered in 2007. Both were found in respiratory tract secretions from patients with respiratory 
illness. This discovery prompted us to investigate the possible involvement of WUPyV and 
KIPyV in this case. DNA extracted from formalin-fixed paraffin-embedded lung, liver, kidney 
and gastrointestinal tissues was tested by real-time PCR for WUPyV, KIPyV and bocavirus 
(Table 3.1). All four tissues were positive for WUPyV. KIPyV and bocavirus were not detected 
in any of the tissues. The entire WUPyV genome (designated Rochester-7029) was subsequently 
sequenced to 4x coverage using multiple primer sets (Accession #FJ794068) and found to be 
5,306 base pairs. The genome contained a 77 base pair terminal duplication in large T antigen 
compared to the reference WUPyV genome (Figure 3.4). The duplication was not predicted to 
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have any effect on the size or sequence of the translated protein as the duplication was 
immediately 3’ to the T antigen stop codon. 
 
Table 3.1 Summary of findings. Numbers in parentheses are Ct values from real-time PCR. 
Study Lung Liver Kidney Gastrointestinal 
Intranuclear inclusions  Positive Positive Positive Positive 
Electron microscopy Positive Not done Not done Not done 
WUPyV PCR Positive (16.6) Positive (30.8) Positive (30.4) Positive (30.2) 
WUPyV IHC Positive Negative Negative Negative 
KIPyV PCR Negative Negative Negative Negative 
Bocavirus PCR Negative Negative Negative Negative 
 
 
Figure 3.4. Nucleotide sequence of the 3’ end of the large T antigen gene from WU 
polyomavirus strain Rochester-7029. The colored boxes show the duplicated sequence, with the 
stop codon underlined.  
 
 
Following detection of WUPyV in the patient’s tissues by real-time PCR, WUPyV-
specific IHC was performed on available tissue to determine whether WU-VP1 protein was also 
present. The liver, kidney and gastrointestinal tissues were all negative (Table 3.1). Strong 
staining was observed in both the lung (Figure 3.5a, c, d, f) and the trachea (Figure 3.5g, i), while 
no staining was seen in serial sections stained with the isotype control antibody (Figure 3.5b, e, 
h). Three staining patterns were seen. In some cells, WU-VP1 staining was primarily in the 
nucleus. In others, the perimeter of the nucleus was strongly positive. Finally, in some cases, the 
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staining was diffuse, making it difficult to discern its position within cells. Interestingly, the 
tracheal staining appeared to be within a submucosal gland.  
 
Figure 3.5. Detection of WU-VP1 in the human respiratory tract. Human lung tissue at 200x 
stained with (A, D) a monoclonal antibody against WU polyomavirus VP1 (NN-Ab06) or (B, E) 
an isotype control antibody. Human tracheal tissue at 200x stained with (G) NN-Ab06 or (H) an 
isotype control antibody. (C, F, I) Higher magnifications of panels A, D and G. Panels C and F 
are at 400x, and panel I is at 600x. 
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Detection of WU-VP1 antigen in alveolar macrophages. Case #2 described below 
detected WU-VP1 in respiratory epithelial cells. We hypothesized that some cells in this 
patient’s lung tissues were also epithelial cells, but we did not explicitly confirm this due to the 
limited amount of lung tissue available. Instead we chose to explore additional hypotheses 
regarding potential tropism of WUPyV based on our recent detection of KIPyV in alveolar 
macrophages (case #4). We performed dIHC using NN-Ab06 and a monoclonal antibody against 
CD68, which primarily labels macrophages and monocytes. Cells double positive for WU-VP1 
and CD68 were detected within the patient’s lung tissue (Figure 3.6). In addition, the cell shown 
in Figure 3.6b was morphologically consistent with a foamy macrophage, a specific morphotype 
of macrophage that is laden with lipid droplets in the cytoplasm (13). KIPyV was also detected 
in a foamy macrophage in case #4 (14). A serial section stained with isotype matched antibodies 
(IgG2b for NN-Ab06 and IgG1 for the anti-CD68 antibody) was negative (not shown).  
 
Figure 3.6. Detection of WU-VP1 in human alveolar macrophages. (A-C) Lung tissue stained 
with NN-Ab06 (blue) and a monoclonal antibody against CD68 (brown). The cell in panel B is 
consistent with a foamy macrophage. Panel A is at 400x; panels B and C are at 1000x. (D) A 
different field of the lung tissue section with another double positive cell at 1000x. 
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Detection of WU-VP1 antigen in association with mucin-producing cells. The initial 
IHC staining of the tracheal tissue revealed positive cells within a submucosal gland. MUC5AC 
is the principal mucin produced by goblet cells, while MUC5B is made by submucosal glands.  
(15). We established two dIHC assays:  (1) NN-Ab06 and a monoclonal antibody against 
MUC5AC and (2) NN-Ab06 and a polyclonal antibody against MUC5B. Both assays were 
performed on control cell pellets (not shown). The MUC5AC dIHC assay yielded clearer 
staining, so we chose to apply this assay to the tracheal tissue.  Figure 3.7 shows WU-VP1-
positive cells in association with clusters of cells showing MUC5-AC positivity. It is unclear 
whether the two antigens colocalize to the same cell. WU-VP1-positive cells were also seen 
separate from MUC5AC-positive cells, suggesting a subset of virus-positive cells do not produce 
mucin. There were two such areas on the tracheal section. 
 
Figure 3.7. Detection of WU-VP1 in close proximity to MUC5AC-positive cells in the trachea. 
Tracheal tissue stained with an anti-WU-VP1 monoclonal antibody (blue) and a monoclonal 
antibody against MUC5AC (brown). Panel A is at 200x, and panel B is at 600x. 
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Case #2:  Detection of WUPyV in respiratory epithelial cells in lungs transplanted 
into a patient with Job’s syndrome. Job’s syndrome is an immune disorder characterized by 
eczematoid dermatitis, recurrent skin and pulmonary infections, elevated IgE and impaired T and 
B cell memory (16). It is caused by dominant-negative mutations in STAT3 (16). A 28-year-old 
woman with Job’s syndrome was seen at the National Institutes of Health Clinical Center six 
months after bilateral lung transplantation. She had bronchoscopic evaluation to follow up on 
endobronchial aspergillosis. Pathological examination of the BAL sample revealed scattered 
cells, primarily columnar bronchial cells, with cytomorphologic changes reminiscent of BKPyV-
infected “decoy cells.” The cells stained positive with PAb419, a monoclonal antibody against 
the SV40 large T antigen. The patient had BKPyV viremia (8.1x10
5 
copies/mL) and viruria 
(6.9x10
9
 copies/mL). JCPyV was also detected in the urine but not in the blood. The BAL was 
very weakly positive for BKPyV by PCR (<250 copies/mL) and negative for JCPyV. Clinical or 
radiographic signs and symptoms of infection were not apparent. Given the positive staining but 
weak PCR results, further analysis of the BAL was performed.  
Non-enveloped virions were purified from the BAL using ultracentrifugation with 
Optiprep (Sigma-Aldrich #D1556) (17). DNA extracted from the virion prep was subjected to 
random-primed rolling circle amplification (RCA) and restriction enzyme digestion, which 
yielded two strong bands. The bands were cloned and identified as WUPyV by Sanger 
sequencing. The complete genomic sequence of the isolate, designated J1 (accession 
#KJ643309), was confirmed by Illumina miSeq analysis of the RCA product. A second WUPyV 
variant with two nucleotide polymorphisms and a single base insertion was also detected in the 
RCA product. No other known viral species (including BKPyV) were observed in the deep 
sequencing.  
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We applied the WU-VP1 IHC assay to formalin-fixed, paraffin-embedded sections of the 
BAL sample. Figure 3.8a shows prominent, dark staining of cells with enlarged nuclei and a 
ground glass appearance characteristic of viral cytopathic changes (arrows). Staining was not 
seen in serial sections stained with the isotype antibody (Figure 3.8b) or with no antibodies (not 
shown).  
 
Figure 3.8. WU-VP1 detected in a BAL from a lung transplant recipient with Job’s syndrome. 
(A) The bronchoalveolar lavage stained with NN-Ab06 or (B) with an isotype control at 600x. 
 
 
Many of the WUPyV-positive cells were cuboidal to columnar in shape with other 
morphologic features consistent with respiratory epithelial cells. To determine their etiology, we 
developed a dIF assay with a polyclonal antibody against WU-VP1 (4), designated NN-Ab01, 
and a monoclonal antibody against cytokeratins. To validate the assay, we first performed IF 
with NN-Ab01 on the positive control 293T cells expressing WU-VP1. Several WU-VP1-
positive cells were observed (Figure 3.9a), while a serial section stained with pre-immune serum 
at the same dilution was negative (Figure 3.9b).  In the dIF assay, we observed cells double 
positive for WU-VP1 and cytokeratin (Figure 3.9c-d), identifying these as epithelial cells. Of the 
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136 WU-VP1-positive cells, 77 (57%) were also cytokeratin-positive. A serial section of the 
BAL stained with an IgG1 isotype matched antibody to the cytokeratin antibody and pre-immune 
rabbit serum was negative (not shown).  
 
Figure 3.9. WU-VP1 detected within respiratory epithelial cells. IF of 293T cells transfected 
with pDEST26-WU-VP1 and stained with (A) a WU-VP1 polyclonal antibody (NN-Ab01) or 
with (B) pre-immune serum. (C) dIF with NN-Ab01 (red) and a monoclonal antibody against 
cytokeratin (green) on the BAL specimen showing a double positive cell at 200x. (D) Field of 
the bronchoalveolar lavage with multiple WU-VP1/cytokeratin double positive cells.  
 
 
We hypothesized that the remaining 43% of WU-VP1-positive, cytokeratin-negative cells 
might be macrophages. However, a dIF assay using NN-Ab01 and the antibody against CD68 
showed separate WU-VP1 and CD68 single-positive cells but no double positive cells (not 
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shown). In addition, a dIF stain using NN-Ab01 and an antibody against CD45, a marker for 
hematopoietic cells, was also negative (not shown). 
Case #3:  Detection of WUPyV in an HIV-positive patient. Sharp et al. previously 
screened 97 autopsy samples of lymphoid tissue by PCR and identified three samples positive for 
WUPyV, all from AIDS patients (18). We stained these specimens using the WU-VP1 IHC 
assay. Only one was positive, which was actually a lung. This sample was obtained from a 32-
year-old male, whose date of HIV diagnosis was unknown. He presented with anal lymphoma 
and received radiotherapy. He subsequently developed bronchopneumonia and septicemia and 
died three months after initial radiotherapy. He also had a previous history of anal herpes virus 
infection and esophageal Candida. Neuropathology showed no significant pathology and no 
evidence of HIV encephalitis. 
There were a relatively low number of darkly staining positive cells scattered throughout 
the section, similar to those seen in Figure 3.10a and c. More diffuse, lighter staining was also 
seen throughout the section. This was not present in serial sections of tissue stained with an 
isotype control antibody (Figure 3.10b) or stained without a primary or without both antibodies 
(not shown). However, we decided to score tissue conservatively and did not count this weaker 
staining as WU-VP1-positive. We attempted to identify these cells using the CD68 dIHC assay, 
but as we moved farther down into the tissue block, WU-VP1-positive cells became fewer and 
fewer, and we were ultimately not able to identify the specific cell types within this lung. 
We were also able to obtain formalin-fixed, paraffin-embedded sections from the 
following:  heart, thyroid, tongue, adrenal gland, kidney, liver, pancreas, pituitary gland, 
prostate, anus and various brain sections. All were negative for WU-VP1 by IHC. 
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Figure 3.10. WU-VP1 detected in a lung from an HIV-positive patient. (A) Lung tissue stained 
with NN-Ab06 or (B) with an isotype control at 400x. (C) Panel A at 600x. 
 
 
Case #4:  Immunohistochemical detection of KIPyV in alveolar macrophages in a 
pediatric transplant recipient. During the course of a recent study to evaluate the prevalence of 
human polyomaviruses in a prospective pediatric transplant cohort (19), we identified one patient 
(#3001) whose nasopharyngeal aspirate sample (NPA) was strongly positive for KIPyV by real-
time PCR. The patient’s clinical parameters have been described in detail (19). In brief, the 
patient was a 17-month-old child who received a bone marrow transplant as treatment for 
Fanconi anemia in April 2009. The patient’s disease course was complicated by recurrent 
pulmonary hemorrhage, severe GVHD, and renal failure.  The patient ultimately died of acute 
respiratory failure and extensive pulmonary hemorrhage several months later. The autopsy of the 
lung revealed evidence of chronic pulmonary hemorrhage with numerous hemosiderin-laden 
macrophages in the alveolar spaces. Diffuse alveolar hemorrhage leading to respiratory failure 
was the listed likely cause of death. Infection was considered less likely due to the negative 
results of routine microbiology testing (via culture and/or PCR). There was no significant 
inflammation or airway fibrosis to suggest GVHD in the lungs. A NPA sample collected 24 days 
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prior to the death of the patient was strongly positive for KIPyV (1.3 x 10
9
 genome copies per 
mL of transport media) (19). 
Tissue blocks obtained at autopsy from 17 different body sites were available for KI-VP1 
IHC testing. These included skin, liver, lung, esophagus, stomach, small intestine, large intestine, 
pancreas, spleen, right kidney, left kidney, bladder, left ventricle, right ventricle and pituitary, 
right adrenal and left adrenal glands. Of these, only the lung was positive by IHC (Figure 3.11). 
Two patterns of cellular staining were seen—strong, dark nuclear staining and weaker, granular 
staining exclusively in the cytoplasm. Several controls were performed on serial sections to 
analyze this staining pattern, including a corresponding IgG2b isotype control (Figure 3.11a) and 
staining performed without the primary antibody or without both the primary and secondary 
antibodies (not shown). The weaker cytoplasmic staining was occasionally seen in controls, but 
the strong nuclear staining was exclusively seen in the KI-VP1 stained tissue. There were 
positive cells scattered throughout the section (similar to Figure 3.11b and c) with a few 
localized regions containing a high density of positive staining cells. 
 
Figure 3.11. IHC of human lung with a KI-VP1 monoclonal antibody. Tissue stained with (A) 
an isotype control or (B) the KI-VP1 antibody (both at 200x). (C) Higher magnification (600x) 
of KI-VP1 staining in panel B. 
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Detection of KI-VP1 in alveolar macrophages. We used a dIHC staining approach to 
identify the cell type(s) that were KI-VP1-positive. Many of the positive cells were found within 
the alveolar spaces and were morphologically consistent with immune cells, so we began our 
analysis by establishing a dIHC assay using the KI-VP1 monoclonal antibody and an antibody 
against human CD45, which marks all cells of hematopoietic origin. Double IHC using the 
CD45/KI-VP1 assay showed clearly staining double positive cells throughout the tissue (Figure 
3.12b, c, e). Of the 105 KI-VP1-positive cells counted in one tissue section, 51 (49%) were also 
CD45-positive. An isotype control (IgG2b for the KI-VP1 antibody) performed on a serial 
section (Figure 3.12a, d) was negative. A hematoxylin and eosin stain showed dark staining 
“grape-like” clusters, morphologically consistent with phagocytic cells (Figure 3.12f). Based on 
these data, we hypothesized that the CD45/KI-VP1-positive cells may be alveolar macrophages 
To test this hypothesis, we established a second dIHC assay using the KI-VP1 
monoclonal antibody and an antibody against human CD68, which primarily marks macrophages 
and monocytes, and applied it to the lung tissue from patient 3001. Clear double staining was 
seen in ~48% of KI-VP1-positive cells (Figure 3.13a-c), while no staining was seen in the 
isotype control (not shown). This demonstrated a subset of the KI-VP1-positive cells were 
alveolar macrophages. In addition, the morphology of the alveolar macrophage presented in 
Figure 3.13c resembles that of a foamy macrophage, a specific morphotype of macrophage 
loaded with lipid droplets (13).  
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Figure 3.12. Detection of KI-VP1 in cells of hematopoietic origin in the lung. Lung tissue 
stained with a dIHC assay using antibodies against (A,D) CD45 (brown) and IgG2b (blue) as an 
isotype control or (B,C,E) CD45 (brown) and KI-VP1 (blue). (F) Hematoxylin and eosin-stained 
lung tissue. Panels A and B are at 400x; panel C is at 1000x; panels D and E are at 600x, and 
panel F is at 200x. 
 
 
We next attempted to identify the remaining subset of KI-VP1-positive cells that were 
CD45-negative. Based on the observation that KI-VP1-positive cells lined the alveoli in case #5 
described below, we established a dIHC assay using antibodies against KI-VP1 and cytokeratin, 
which labels epithelial cells. While cells staining single positive for either KI-VP1 or cytokeratin 
were evident, no double positive cells were seen (Figure 3.14), suggesting KIPyV was not 
present in epithelial cells in this lung specimen. One caveat to this interpretation is the absence of 
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a gold standard positive control (i.e. epithelial cells known to express KI-VP1 in lung tissue) to 
validate the cytokeratin/KI-VP1 double stain in the context of lung tissue.  
 
Figure 3.13. Detection of KI-VP1 in alveolar macrophages. Double IHC staining with antibodies 
against CD68 (brown) and KI-VP1 (blue) at (A) 400x and (B) 1000x. (C) A second double 
positive cell from another field of the tissue at 1000x. 
 
 
Figure 3.14. Double IHC of the lung with monoclonal antibodies against KI-VP1 (blue) and 
cytokeratin (brown) at 600x. 
 
 
Case #5:  Immunohistochemical detection of KIPyV in lung and spleen. Sharp, et al. 
(see case #3 above) also identified four samples positive by PCR for KIPyV, three from AIDS 
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patients and one from an HIV-negative patient (18). All four were tested using the KI-VP1 IHC 
assay. One spleen sample had KI-VP1-positive cells scattered throughout the section with a few 
localized regions containing a high density of positive staining cells (Figure 3.15a-c).  This 
sample was derived from a 42-year-old HIV-positive male who had initially presented with 
peripheral neuropathy and atypical mycobacterial infection. He was re-admitted four months 
later for CMV retinitis, and his condition continued to deteriorate until death. Autopsy showed 
disseminated mycobacterial infection, CMV esophagitis, low grade CMV encephalitis and 
vacuolar myelopathy.  
Most of the KI-VP1 positive cells were in areas of white pulp, which also showed poorly 
formed granulomas attributed to a mycobacterial infection, according to the autopsy report. One 
such example with positive cells surrounding a blood vessel consistent with splenic white pulp is 
shown in Figure 3.15b-c. The isotype matched control antibody (J6.36) targeting the E2 
glycoprotein of Hepatitis C virus (20) yielded no staining, consistent with specific anti-KI-VP1 
staining (Figure 3.15a). Based on morphology and the detection of KI-VP1 in alveolar 
macrophages in the previously described case (case #4), we suspected hematopoietic cells may 
harbor KIPyV. Double staining of KI-VP1 with CD45 or CD68, however, yielded only single 
positive cells (Figure 3.16a, b). Given these negative results, we hypothesized that the KI-VP1-
positive cells may be endothelial cells, so we established a dIHC assay with the anti-KI-VP1 
antibody and an antibody against CD31, which primarily marks endothelial cells. However, only 
single positive cells were seen (Figure 3.16c).  Therefore, the identity of the positive staining 
cells in the spleen is currently unknown. 
We obtained sections of all other available tissues from this patient from the tissue bank 
for further analysis. These included the adrenal gland, carotid artery, colon, heart, ileum, kidney, 
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liver, lung, pancreas, pituitary gland, prostate, testis, thyroid gland, tongue and a lymph node. 
Besides the spleen, only the lung specimen was positive by IHC for KI-VP1 with strong staining 
throughout the tissue as represented in Figure 3.15d-f. Closer inspection of the lung showed KI-
VP1 staining of some alveolar surfaces, raising the possibility that the infected cells might be 
pneumocytes. In addition, other cells (Figure 3.15f, arrows) of unknown identity that did not 
border the alveolar spaces were also positive, suggesting that KIPyV infects multiple cell types 
present in the lung. Definitive identification of the specific cell types staining positive in this 
tissue was not possible due to the lack of available tissue. According to the autopsy report, the 
lungs showed bronchopneumonia, but no granulomas or acid fast bacilli were identified.  The 
lung weights and pathological findings did not suggest an acute interstitial pneumonia.  
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Figure 3.15. IHC of human spleen and lung with a KI-VP1 monoclonal antibody. Tissue 
surrounding a splenic blood vessel consistent with splenic white pulp stained with (A) the 
isotype control or (B) the KI-VP1 antibody (both at 400x). (C) Hematoxylin and eosin staining 
of the same splenic area at 200x. Gas exchange tissue near a bronchiole stained with (D) the 
isotype control at 200x or with (E) the KI-VP1 antibody at 200x and (F) 600x. 
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Figure 3.16. Additional dIHC stains of human spleen. Double IHC of spleen with monoclonal 
antibodies against (A) KI-VP1 (blue) and CD45 (brown) or (B) KI-VP1 (blue) and CD68 
(brown) both at 600x. (C) Double IHC of the spleen with monoclonal antibodies against KI-VP1 
(blue) and CD31 (brown) at 400x. 
 
 
DISCUSSION 
Detection of viral antigen in multiple tissues. We detected WU-VP1 in lung and 
tracheal tissues and in a BAL and KI-VP1 in lung and splenic tissues for the first time using 
newly developed IHC assays (Table 3.2). Putative WUPyV virions were also observed in the 
lung tissue of case #1 by electron microscopy. We identified a subset of both the WU-VP1-
positive and KI-VP1-positive lung cells as alveolar macrophages, providing the first example of 
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a specific cell type in which these viruses are detected. In addition, WU-VP1 was detected in 
respiratory epithelial cells and in cells associated with MUC5AC (a mucin)-positive cells.  
 
Table 3.2. Summary of results. 
Virus Case Tissue Cell type 
WUV 
1 
Lung 
1. Macrophages 
2. CD68-negative population 
Trachea 
1. Positive cells in close proximity to Muc5AC-positive cells 
2. Muc5AC-negative population 
2 BAL 
1. Epithelial cells 
2. Non-epithelial population 
    -CD68 dIF & dIHC negative 
    -CD45 dIF negative 
3 Lung 
CD68 dIHC negative 
Remaining tissue is mostly negative 
KIV 
4 Lung 
1. Macrophages 
2. CD45-negative population 
    -Cytokeratin dIHC negative 
5 
Spleen CD45,CD68 & CD31 dIHC negative 
Lung Unknown – no tissue left 
 
Detection of WU-VP1 and KI-VP1 in alveolar macrophages. The detection of viral 
antigen in alveolar macrophages in cases #1 and #4 was unexpected. The majority of prior 
WUPyV and KIPyV studies focused on respiratory secretions and relied on PCR of bulk-
extracted DNA, making it impossible to determine specific cell types. Nonetheless, the simplest 
hypotheses regarding WUPyV and KIPyV tropism have focused on respiratory epithelial cells, 
the cell types infected by common respiratory viruses such as RSV (21) and influenza (22). 
While the IHC results alone do not prove that WUPyV and KIPyV can productively infect 
macrophages, they do demonstrate expression of capsid protein from the late region of the 
genome, a step in the polyomavirus life cycle that is generally thought to occur concomitantly 
with DNA replication (23). These results also suggest that efforts to develop in vitro culture 
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systems for WUPyV and KIPyV should explore the possibility that macrophage and monocyte 
cell lines may be permissive for productive infection. 
Alveolar macrophages are long-lived, terminally-differentiated cells that permanently 
reside in the lung. They are thought to be one of the first cell types to respond to pathogens (24). 
The identification of alveolar macrophages as a potential site of WUPyV and KIPyV infection 
greatly expands our understanding of viral tropism and provides new insights into the biology of 
these viruses. The infection of macrophages and monocytes by BKPyV (25), early hematopoietic 
progenitor cells by JCPyV (26) and detection of MCPyV (27) in monocytes have been reported. 
Alveolar macrophages display α-2,3- and α-2,6-linked sialic acid (28), both of which are known 
receptors for other polyomaviruses. BKPyV and murine polyomavirus both bind to α-2,3-linked 
sialic acid, and JCPyV binds to α-2,6-linked sialic acid (29). It is currently unknown what 
receptors are utilized by WUPyV and KIPyV, but it is possible that they might use similar 
receptors to BKPyV and JCPyV.  
The detection of WU-VP1 and KI-VP1 in alveolar macrophages could arise from one or 
more possible scenarios. First, alveolar macrophages may be susceptible to productive infection. 
Alternatively, it is also conceivable that circulating monocytes become infected in the 
bloodstream and remained infected after differentiation into alveolar macrophages in the lung. 
Third, other respiratory viruses, such as type A influenza virus, are known to abortively infect 
alveolar macrophages (30), where infection and subsequent steps of the viral life cycle occur but 
no virions are produced. Finally, we cannot rule out the formal possibility that the presence of 
WU-VP1 and KI-VP1 merely reflects phagocytosis of other virus infected cells. However, given 
the observation that viral staining is nuclear, this seems like an unlikely option. Bona fide 
infection versus abortive infection of macrophages by WUPyV or KIPyV would likely lead to 
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different outcomes, as is seen during influenza A infection (30). For example, an abortive 
infection would make the macrophage a dead end host and might allow the human host to mount 
a more effective immune response and delay viral spread. Conversely, a productive infection, 
whether initiated in the blood or lung, could incite a pro-inflammatory response from the 
infected macrophages, leading to greater immunopathology and increased viral spread.  
Detection of WU-VP1 in association with mucin-positive cells. In addition to detection 
in alveolar macrophages, WU-VP1 protein was also detected in close proximity to MUC5AC-
positive cells in tracheal tissue from case #1. The detection of WUPyV in tracheal tissue was 
unexpected and further expands the known tissue tropism of the virus. As previously mentioned, 
MUC5AC is a mucin primarily produced by goblet cells in the airway. Several viruses have been 
described in glandular tissue. Adenovirus was grown in primary cultured peribronchial 
submucosal gland cells (31), while rhinovirus was grown in human respiratory submucosal gland 
cells (32). Severe acute respiratory syndrome (SARS) associated virus antigen and RNA were 
detected in tracheal/bronchial serous gland epithelium (33). In addition, BKPyV has been shown 
to replicate in salivary gland cells (34, 35). The role of WUPyV in the trachea is currently 
unknown. However, viral shedding from the trachea or respiratory tissue could contribute to 
transmission of the virus via the respiratory route. 
Detection of WU-VP1 in respiratory epithelial cells. WU-VP1 was also detected in 
bronchial epithelial cells in the BAL from case #2, a finding which was not unexpected. The 
presence of nuclease-resistant viral DNA from the Optiprep gradient and the detection of WU-
VP1, which is thought to be expressed concomitantly with DNA replication (23), suggests a fully 
productive infection occurred. Although we attempted to identify a second population of WU-
VP1-positive, cytokeratin-negative cells, the etiology of these cells remains uncertain.  
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Summary of cases. In all of the cases presented here, the patients were 
immunocompromised, either through a transplant or through infection with HIV. Other human 
polyomaviruses are thought to exclusively cause disease in immunocompromised hosts, and 
these cases suggest that immunosuppression may also play a role in WUPyV and KIPyV 
infection. All five cases had respiratory samples with detectable virus, supporting the hypothesis 
that the lung is an important site for both WUPyV and KIPyV infection. While it is impossible to 
prove causation or establish WUPyV and KIPyV as human pathogens from these cases, it does 
raise interesting questions about the pathogenicity of the viruses, especially in the respiratory 
tract, and their role in human infection, particularly in patients who are immunosuppressed. 
However, the five cases presented with unique clinical features and disease pathologies:  
WUPyV cases. The likely cause of death for this pediatric bone marrow transplant 
recipient (case #1) was viral pneumonitis, and the patient suffered from severe acute respiratory 
distress syndrome shortly before death. IHC for several viruses were negative, as were attempts 
to grow virus from patient samples. Later testing by real-time PCR was also negative for KIPyV 
and bocavirus. WUPyV was the only virus detected in the patient’s samples using PCR, IHC and 
electron microscopy. In addition to the lung, the liver, kidney and gastrointestinal tissues were 
also positive for WUPyV by real-time PCR and had similar intranuclear inclusions, although the 
viral loads were significantly lower. Electron microscopy was not attempted on these three 
tissues, and IHC was negative. However, it is possible the amount of virus present in these 
samples was below the limit of detection of our IHC assay.  
 In case #2, the patient suffered from Job’s syndrome, a primary immunodeficiency, and 
received a bilateral lung transplant six months before demonstrating WUPyV-positivity. Job’s 
syndrome has not previously been associated with polyomavirus susceptibility. However, to our 
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knowledge, lung transplants have not been performed in Job’s syndrome patients before now, 
and it is possible that the addition of immunosuppressant medications could have altered 
susceptibility to viral infection. Following the bronchoscopic evaluation, the patient received 
immunoglobulin replacement therapy, which could have affected the viral infection; 
immunosuppressant medications were also decreased. A repeat evaluation three months later did 
not show any viral cytopathic changes, and SV40 staining was negative. 
In contrast to the first two cases, the final WUPyV case (case #3) was an HIV-positive 
adult male, with several HIV-related illnesses at the time of death. Previous PCR results were 
positive for WUPyV. Lung tissue stained by IHC was only weakly positive for the virus, and we 
were unable to identify the specific cell types staining positive. Collectively, these results 
demonstrate WUPyV can be detected in lung samples from multiple immunocompromised 
patients. While the pathogenicity of WUPyV is still unclear, there is strong evidence for a 
WUPyV infection in case #1. In addition, respiratory-related issues contributed to death in cases 
1 and 2, raising intriguing questions about the role of WUPyV in these cases.  
KIPyV cases. Case #4 (patient 3001) was a pediatric patient who underwent a bone 
marrow transplant with multiple complications, including severe GVHD, and died from acute 
respiratory failure and extensive pulmonary hemorrhage. In contrast, the other patient (case #5) 
was an HIV-positive adult with multiple AIDS-defining illnesses at the time of death. The 
detection of KI-VP1 in the spleen of the adult HIV case and its absence in patient 3001 may 
reflect a distinct modality of KIPyV infection or possibly a dependence on HIV-mediated 
immunosuppression. Regardless, the IHC detection of KI-VP1 in the spleen of this patient 
corroborates the published PCR results (18), and provides evidence that additional specific cell 
types harbor KIPyV. Collectively, these results demonstrate that KI-VP1 can be detected in 
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multiple distinct cell types in more than one tissue type in the human body and suggest the 
possibility that additional parameters, such as host immune status or age, may be important 
factors affecting viral tropism. While the role of KIPyV in human disease remains to be 
determined, it is interesting to speculate about a potential role in respiratory illness given the 
high titers of KIPyV in patient 3001.  
Final summary. In conclusion, we established immunohistochemical assays to detect 
WUPyV and KIPyV antigen in human tissue. We also demonstrated KI-VP1-positive staining in 
two lungs and one spleen from two separate patient cases and WU-VP1-positive staining in two 
lungs, a BAL and one trachea. Further analysis revealed a subset of the WUPyV and KIPyV-
positive cells was alveolar macrophages, and subsets of the WUPyV-positive cells were 
respiratory epithelial cells or near mucin-positive cells in the trachea. Finally, putative WUPyV 
virions were seen in the lung tissue of one patient. These discoveries further our understanding of 
WUPyV and KIPyV biology and tropism. Moreover, the knowledge that WUPyV and KIPyV 
can both be detected in macrophages will benefit future efforts to develop cell culture systems 
for propagation of these viruses. The role of WUPyV and KIPyV as human pathogens remains 
unclear, although the evidence for their infection of the respiratory tract is building.  
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CHAPTER 4 
 
 
Development of a cell culture system for WU polyomavirus 
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ABSTRACT 
 WU polyomavirus (WUPyV) was discovered in 2007 in a respiratory sample from a child 
with pneumonia. While the virus infects the majority of the population, it is unclear whether it is 
causes disease in humans. Study of WUPyV has been limited by the lack of a cell culture system 
in which to grow the virus, a tool which is also critical to establishing disease causality. 
Although a replication system using a genomic clone is established, only one round of 
replication is achieved. This system does not represent a natural infection, and the virus cannot 
complete its life cycle by re-infecting neighboring cells. We attempted to establish a cell culture 
system for WUPyV. We used virus generated via the replication system to infect two primary 
human cell types and 12 immortal human cell lines. No viral replication was detected in most of 
these cell lines. However, increases in viral DNA over the course of the infection were detected 
in the monocytic cell lines KG-1, THP-1, U-937 and HL-60. Further studies with THP-1 cells 
showed this effect was reproducible and also seen following passage of infected cell lysates. 
Despite this promising data, no virions were seen by electron microscopy; no viral protein was 
detected by Western blot; and analysis of RNA transcripts was inconclusive. While we were not 
able to establish a robust cell culture system for WUPyV, these studies provide a framework on 
which to base future efforts. 
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INTRODUCTION 
WU polyomavirus (WUPyV) was discovered in 2007 in a nasopharyngeal aspirate (NPA) 
from a three-year-old Australian child suffering from pneumonia (1). Subsequent studies, 
including those described in Chapter 3, described the viral epidemiology and tropism and began 
exploring potential disease associations. However, the gold standard for establishing disease 
causality is to fulfill Koch’s postulates, which necessarily requires the virus to be grown in cell 
culture. As no such system currently exists for WUPyV, it is a fundamental barrier to both 
establishing disease causality and exploring the basic biology of this virus. 
The two well-established human pathogens BK and JC polyomaviruses (BKPyV, JCPyV, 
respectively) can be cultured in mammalian cells. JCPyV grows in a very limited number of cell 
types in culture, including human glial cells and tonsillar stromal cells (2). BKPyV infects a 
greater variety of cells, including African green monkey kidney cells, human embryonic kidney 
(HEK), human diploid lung fibroblasts, infant urothelial cells, human fetal brain cells, monkey 
kidney cells and human embryonic lung cells (3, 4). The other human polyomaviruses have been 
found in a variety of sample types (Table 4.1), but none has yet been grown in cell culture. 
However, a replication system similar to that described below for WUPyV was established for 
Merkel cell polyomavirus (MCPyV) (5).  
Prior to the studies noted in Chapter 3, WUPyV DNA was detected in a variety of sample 
types, but no specific cell tropisms were identified. The detection of WUPyV protein in alveolar 
macrophages and respiratory epithelial cells heavily influenced subsequent work. It is important 
to note, however, that while this tropism data was useful in the selection of different mammalian 
cells in which to attempt culture of WUPyV, BKPyV and JCPyV protein can be detected in cell 
types within the human body that do not support viral infection when grown in culture.  
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Table 4.1. Human polyomaviruses are detected in a variety of specimen types (6-16). 
Respiratory sample is abbreviated “RS” and includes NPAs and other respiratory tract samples.  
Virus 
Detected in: 
RS Blood Urine Stool 
BKPyV X X X X 
JCPyV X X X X 
KIPyV X X  X 
WUPyV X X  X 
MCPyV X X X X 
HPyV6 X   X 
HPyV7 X  X X 
TSPyV X   X 
HPyV9  X X  
MWPyV X   X 
STLPyV   X X 
HPyV12    X 
NJPyV  X   
 
 
 
While no infectious cell culture system is currently available for WUPyV, a replication 
system using a WUPyV genomic clone was established in Vero cells (17). Genomic clones are 
widely used in the polyomavirus field and can be transfected into permissive cells to recapitulate 
one round of the post-entry viral life cycle. However, the newly formed virions (referred to as 
recombinant WUPyV, rWUPyV) cannot complete the cycle by infecting new cells. In the 
replication system, the viral genomic clone (cWUPyV) is transfected into Vero cells, and viral 
DNA and protein are detectable in the cells and supernatant by three days post-transfection 
(Figure 4.1). As no WUPyV culture system exists, we cannot assess the infectivity of these 
particles, although studies described in the results do address this issue. While this system is 
useful for studying some aspects of viral biology and can be used to produce virions, it is not a 
natural infection, which fundamentally limits the type of studies that can be performed using it. 
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Figure 4.1. Establishment of a WUPyV replication system (17). A) Supernatants from Vero cells 
show viral capsid protein expression starting at day 3 post-transfection when additional early 
region is also transfected (cWUPyV-wt + pER). A clone with a stop codon in the LT (cWUV-
4981) was included as a negative control. B) Vero cell transfected with cWUPyV and pER at 
4000x. C) Vero cell transfected with cWUPyV and pER at 40,000x. Scale bar is 200 nm. D) 
Supernatants from Vero cells show WUPyV DNA starting at day 3 post-transfection. 
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Despite the importance of a cell culture system for study of WUPyV, no such system 
currently exists and is a fundamental barrier to a better understanding of viral biology and 
pathogenesis. While numerous attempts to develop an infectious cell culture system for WUPyV 
are described here, they were ultimately unsuccessful. Data from rWUPyV infection of THP-1 
cells was initially promising, although later experiments were more inconclusive. It is unclear 
whether the initial positive results were an artifact or a more complicated explanation is 
warranted. Establishing a fully functional culture system for WUPyV remains an important goal, 
and the experiments described here will provide a foundation on which to base future studies.  
 
MATERIALS AND METHODS 
Density gradient ultracentrifugation. Vero cells (1x10
6
 cells/60mm dish) were transfected 
with 6.4 micrograms (ug) of the WUPyV genomic clone (cWUV-wt) and 6.4 ug of a plasmid 
(pcDNA3.1/Hygro+ from Invitrogen) containing the WUPyV early region (pER) using 
Lipofectamine 2000 (Invitrogen) in OptiMEM media (Gibco). At three days post-transfection, 
the cells were trypsinized, pelleted and resuspended in Buffer A (50mM NaCl, 10mM Tris-HCl 
pH 8, 0.01% TritonX-100, 0.01mM CaCl2). Lysates were freeze-thawed three times in DMEM 
(Gibco) containing 10% FBS and pelleted over a 20% sucrose cushion in a Beckman Optima L-
100 XP ultracentrifuge using a SW41Ti rotor (Beckman Coulter) at 25,000 rotations per minute 
(rpm) for one hour. The pellet was resuspended in 1.0 mL TEN buffer (0.1M Tris-HCl pH 8, 
0.01M EDTA, 1M NaCl), which was layered over a 13 mL 30-68% sucrose step gradient (5 mL 
30% sucrose over 6 mL 68% sucrose) and spun in the SW41Ti rotor at 35,000 rpm for 23 hours. 
Six fractions, 2.0mL each, were collected using an Auto Densi-Flow fractionator (Labconco). A 
Western blot was performed using 20ul of each fraction. The fraction containing the most VP1 
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protein as determined by immunoblot was buffer exchanged from 2.0 mL sucrose solution to 1.0 
mL Buffer A using an Amicon Ultracel-100k centrifugal concentrator. The sample was then 
layered over a 13 mL 2M-3M cesium chloride gradient prepared using the Auto Densi-Flow 
fractionator and spun in the SW41Ti rotor at 35,000 rpm for 24 hours. Twenty fractions of 
approximately 0.6mL were collected using the Auto Densi-Flow fractionator. The density of 
each fraction was determined using a Thermo Spectronic refractometer (Thermo Scientific). 
Each fraction was buffer exchanged from 600 uL cesium chloride solution to 100 uL Buffer A, 
and 20 uL was used for Western blot. Fifty microliters of each sample was DNase treated with 
100U of DNaseI (Fermentas) in 2x Fermentas DNase Buffer for one hour at 37°C. DNA was 
then extracted. The 25ul real-time PCR (qPCR) reactions included 12.5 uL of Universal TaqMan 
real-time PCR master mix (ABI), 5 uL of extracted sample, 12.5 pmol of each primer and 4 pmol 
of probe. Primers and probe were from the previously published WU-C assay, which targets the 
non-coding control region (NCCR) (18). Each sample was tested in triplicate. Reactions were 
run on a CFX96 thermocycler (BioRad) and analyzed according to recommended BioRad 
parameters. A standard curve was run on each plate to determine the copy number. 
Infection of primary cells. All infections of primary cells were done by Andrew Pekosz at 
Johns Hopkins University. Similar data to that noted in Figure 4.1 was obtained from 
transfection of the WUPyV genomic clone into 293T cells. Cell lysate containing rWUPyV from 
the 293T replication system was freeze-thawed three times, diluted 1:50 in culture media and 
used to infect primary human nasal epithelial cells (hNEC) and primary human tracheal 
epithelial cells (hTEC) in quadruplicate for two hours at 33°C or 37°C, respectively. Mock 
infections were also performed in quadruplicate. Cells were infected from both the apical (100 
uL inoculum) and basolateral (500 uL inoculum) sides simultaneously. Cells were cultured as 
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previously described (19). Each cell type (hNEC or hTEC) originated from a single donor. 
Cultures were washed and incubated with 1000 uL (hNEC) or 500 uL (hTEC) of the appropriate 
media on the basolateral side. At two, 48 and 96 hours post-infection (hpi), media was added to 
the apical chamber (200 uL for hNEC, 100 uL for hTEC) for 10 min before collection and 
storage at -80°C. The basolateral media was also harvested and stored. At the two and 48 hour 
time points, the basolateral media was replaced, and the cells continued incubation. At 96 hpi, 
the cells were scraped and pelleted, and the cell pellets were stored at -80°C. This experiment 
was later repeated (five replicates) in the same manner. 
 A portion of the cell pellet was passaged by resuspending the cells in media, freeze-
thawing three times and using this lysate as inoculum to infect a fresh culture of hNECs in 
quadruplicate. The rest of the experiment was performed as noted above.  
Infection of immortal cell lines. Adherent cell lines were plated at 25% confluence in media 
containing antibodies against interferon alpha (IFNα, pbl interferon source #21100) and tumor 
necrosis factor alpha (TNFα, R&D Systems #MAB610) (both at 10 ug/mL) in a 24-well plate 24 
hours  before infection. Suspension cell lines were plated in the same way but at a concentration 
of 2x10
5
 cells/mL in 0.5 mL media. All cells were cultured as recommended by ATCC and split 
at least once before infection. When media changes were performed or an aliquot collected from 
the suspension cells, they were centrifuged; the supernatant was removed; and they were 
resuspended in the appropriate media. For both cell types, immediately prior to infection, the 
media was changed to serum-free media without antibodies. Infections were performed in the 
minimum amount of media needed to cover the well. Cells were infected with rWUPyV from the 
Vero replication system in duplicate for one and one-half hours at an approximate multiplicity of 
infection (MOI) of one or 100. MOI was based on the number of viral genome copies calculated 
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by qPCR analysis of DNase-treated inoculum. Following infection, the media was changed back 
to regular media containing the two antibodies. Aliquots of the supernatant were taken at two, 
24, 72, 120 and 144 hpi and replaced with fresh media. At two and 24 hpi, this media contained 
the two antibodies, while no antibodies were included in media added at the later time points. 
Cells were checked daily for cytopathic effects (CPE). After the final time point was taken, the 
cells were scraped, and the cell pellet was frozen at -80°C. Half of the cell pellet was later 
resuspended in media, freeze-thawed three times and used as the inoculum for a new infection of 
fresh cells. This was repeated twice more, for a total of three passages. No antibodies were 
included in the media during the passages. Supernatant aliquots were collected at two, 96 and 
144 hpi. Slight modifications of this protocol were utilized for the A549, MRC-5, WI-38, Calu-3 
and hs198.ton cell lines. These cell lines were infected for two hours in media containing serum 
and the two antibodies. The media was not changed post-infection.  
 For the next infection (Figure 4.9), THP-1 cells were plated in a T75 flask at 2x10
5
 
cell/mL in 10 mL media containing the two antibodies. Cells were infected with rWUPyV at an 
MOI of 100 in 5.0 mL serum-free media without antibodies for two hours. Following infections, 
the cells were centrifuged, and the media was replaced with normal media plus antibodies. At 
zero, 24, 72 and 120 hpi, a 2.0 mL aliquot was removed. Media was not replaced. The cells and 
supernatant were separated by centrifugation, and both were analyzed as noted below. 
 For the final infection (Figures 4.10-11), cells were plated at 1x10
5
 cell/mL in a 6-well 
plate with 2.5 mL media containing the anti-IFNα and anti-TNFα antibodies plus an antibody 
against interferon beta (IFNβ, R&D Systems #AF814). Cells were infected for two hours in 
duplicate with rWUPyV diluted in 1.25 mL serum-free media without antibodies. Three 
concentrations of diluted rWUPyV were used (1:10, 1:100 and 1:1000). Following the two hour 
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infection, the media was replaced with regular media containing the three antibodies. Aliquots 
were collected at zero, 12, 24, 48, 72 and 96 hpi. The media was not replaced. At the final time 
point, a portion of the cells were passaged into a new 6-well dish at 1x10
5
 cell/mL. The 
remaining cells and supernatant were processed as noted below. 
DNA extraction. DNA was extracted from the primary cell supernatants using an Ampliprep 
Cobas extractor (Roche). We used the Qiagen Blood and Tissue kit to extract DNA from the 
immortal cells and their supernatants.  
Analysis of viral DNA by real-time PCR. Two qPCR assays were used for these studies. 
Analysis of primary human cell infections was accomplished using the WU-C assay noted above. 
We used the WU-B assay (18), which targets the LTAg, with the same conditions for analysis of 
the immortal cell line infections. Reactions were cycled using either an ABI 7500 real-time 
thermocycler (Applied Biosystems) or the aforementioned CFX96. A standard curve of serial 
dilutions (5 to 5 x 10
6
 copies per reaction) of a plasmid containing the cognate target sequence 
was run on each plate, from which actual DNA copy numbers of each sample were extrapolated.  
Extraction of RNA and analysis by RT-PCR. RNA was extracted from cells using the Qiagen 
RNeasy kit. RT-PCR was performed using primers flanking the splice junction, AG86 (5’-
TGCAAGAGTGTGTTAGTACAGTG-3’) and AG108 (5’-CCAGGAGATTTAGGCATTTCC-
3’), and the Qiagen one-step RT-PCR kit. Primers were annealed at 52°C with 40 cycles total.  
 
RESULTS 
Analysis of virions produced by a WUPyV replication system. A replication system 
using a WUPyV genomic clone was previously established  in our lab (Figure 4.1) (17), although 
it was impossible to determine whether virions produced by this system were infectious. 
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However, the densities of empty (1.29 g/mL) and mature (1.33 g/mL) polyomavirus particles 
resulting from a productive infection were well characterized. To determine the densities of viral 
particles produced in the WUPyV replication system, we performed cesium chloride density 
gradient ultracentrifugation as detailed in Figure 4.2a. The presence of WUPyV DNA was 
assayed by qPCR, and VP1 protein expression was assayed by Western blot (Figure 4.2b, c). 
Extrapolation of the qPCR data indicated 1.2 x 10
8
 copies of WUPyV DNA were produced per 
60mm plate (2.1x10
6
 cells) of transfected Vero cells. A protein peak at 1.28 g/mL corresponded 
to the density of putative empty capsids. A second protein peak at 1.33 g/mL matched the single 
DNA peak and corresponded to putative mature virions. These values matched well with 
established virion densities for the polyomavirus family.  
Infection of primary respiratory cells with rWUPyV. Polyomaviruses typically 
display marked species specificity (20). Previous studies detected WUPyV in various respiratory 
tract secretions and in lung and tonsillar tissue. Based on this data, we first focused on 
respiratory cells. Primary respiratory cell types have been shown to support infection by a 
number of respiratory viruses, including rhinovirus (21, 22), respiratory syncytial virus (23, 24) 
and Andes virus (19). In collaboration with Andy Pekosz at Johns Hopkins University, we 
infected hNECs and hTECs, both primary cell types, with rWUPyV. We infected from both the 
basolateral and apical sides of these polarized cells, as different viruses have been shown to 
selectively infect from one or the other side. For example, influenza preferentially infects the 
apical membrane (25), while adenovirus prefers the basolateral (26).  
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Figure 4.2. Determination of the density of rWUPyV viral particles. A) Schematic of WUPyV 
cesium chloride density gradient protocol. B) Viral genome copies in each density gradient 
fraction. C) Western blot of WUPyV VP1 protein in each density gradient fraction. 
 
 
 
Human nasal epithelial cells and hTECs were infected or mock infected in quadruplicate 
with rWUPyV. DNA extracted from the supernatant (supe) was assayed at two, 48 and 96 hpi 
using a qPCR assay targeting the WUPyV NCCR (18). At 96 hpi, the cells were collected for 
analysis by Western blot. If viral replication was occurring, we would expect to see increasing 
amounts of viral DNA in the supernatant over the course of the infection. A reproducible 
increase in viral DNA in the apical supernatant was detected in three of the four replicates 
(Figure 4.3a). The fourth replicate, well A, showed a decrease in viral DNA over time. As this 
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trend was opposite from the other three replicates, we re-extracted nucleic acid from the well A 
supernatant. The qPCR results were contradictory to those from the first extraction (Figure 4.3b).  
 Results from qPCR of the basolateral supernatants were inconclusive but not promising 
(Figure 4.3c). The basolateral supernatant from well A was again extracted twice, yielding 
somewhat different results. Well B showed an initial increase, followed by a plateau. Well C 
showed a sharp increase, but no viral DNA was detectable by 96 hpi. Finally, Well D showed an 
initial decrease, followed by a sharp increase. No meaningful amount of viral DNA was detected 
in the mock infections (wells E-H). Protein was extracted from the cell pellets collected at 96 hpi 
for Western blot, but no WUPyV protein was detected. Overall, viral DNA consistently 
increased on the apical side of the hNECs, but no reproducible increase was seen on the 
basolateral side.  
We did not detect any replication occurring following rWUPyV infection of the hTECs. 
(Figure 4.4). Only one well had detectable viral DNA in all three time points (well B-apical). 
This well showed an initial increase from two to 48 hpi, but viral DNA decreased sharply by 96 
hpi. Wells A and B had detectable viral DNA at 48 and 96 hours post-infection on the basolateral 
side, but both showed slight decreases over time. Well A only had viral DNA detectable at 48 
hpi. Well C had no detectable viral DNA at any time points on either side. Well D also had no 
detectable viral DNA on the basolateral side, and viral DNA decreased over time on the apical 
side, although there was no detectable DNA at 48 hpi. Given these results, no further 
experiments were conducted with the hTECs. 
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Figure 4.3. Viral DNA detected in supernatants from hNECs infected with rWUPyV. Each well 
is an independent replicate. (A) Apical supernatants, wells B-D; (B) Apical supernatant, well A, 
which was extracted twice; (C) Basolateral supernatants. Well A was again extracted twice.  
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Figure 4.4. Viral DNA detected in supernatants from hTECs infected with rWUPyV. Each well 
is an independent replicate. a, apical; b, basolateral. 
 
 
We repeated the hNEC infection with similar infection parameters and collected 
supernatants from the apical and basolateral sides at two, 48 and 96 hpi (Figure 4.5). Basolateral 
supernatants from all five replicates showed a slight initial increase (~ 0.5 log) in viral DNA 
from two to 48 hpi, followed by a plateau or very slight decrease from 48 to 96 hpi. Four of the 
five replicates showed mostly decreasing viral DNA in the apical supernatant. However, one 
replicate, well C, showed a steady increase of over one log. No viral protein was seen by 
Western blot of protein extracted form cell pellets harvested at 96 hpi. 
We also used lysate collected from the first hNEC infection to infect fresh hNEC cells. If 
an infection was occurring, we would expect production of virions, which would infect new 
hNEC cells upon inoculation. As shown in Figure 4.6, a very slight increase in viral DNA was 
seen in basolateral supernatant from two of the four replicates, but no other sample showed any 
evidence of viral replication. No evidence of viral protein was detected by Western blot. 
99 
 
Figure 4.5. Viral DNA detected in supernatants from hNECs infected with rWUPyV. Each well 
represents an independent replicate. a, apical (blue); b, basolateral (red).  
 
 
Figure 4.6. DNA detected in supes from hNECs infected with lysate passaged from a rWUPyV 
hNEC infection. Each well is an independent replicate. a, apical (blue); b, basolateral (red). 
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While the initial infection showed increases in viral DNA of one log in the apical 
supernatant (Figure 4.3), when we repeated the same infection (Figure 4.5) or passaged lysate to 
fresh hNECs (Figure 4.6), most wells showed a decrease in viral DNA.  When an increase was 
seen, it was very slight, with the exception of one well (well A, apical side, Figure 4.5). Given 
this unconvincing data, no further infections were attempted in the hNECs. 
Infection of immortal cell lines with rWUPyV. Only infections of immortal cell lines 
derived from human cells were attempted due to the species specificity of polyomaviruses (20). 
Based on the detection of WUPyV in alveolar macrophages and respiratory epithelial cells, we 
chose cell lines of either respiratory origin or of the myeloid lineage. We also included 
antibodies against TNFα and IFNα in the culture media pre- and post-infection, which has been 
shown to promote viral infection in cell culture by countering the host cell’s innate immune 
response (27). Results from rWUPyV infections are shown in Table 4.2. No evidence of viral 
replication was observed in eight of the 12 cell lines (not shown). However, in four lines, KG-1, 
THP-1, U-937 and HL-60, an increase in viral DNA in the first 24 hpi was observed (Figure 4.7). 
As results from these four cell lines were similar, we chose to further characterize the infection 
in one cell line, THP-1. We repeated the THP-1 infection at an MOI of 100 with similar 
experimental parameters, which yielded similar results in three of four replicates (not shown). 
Lysate from the initial infection of THP-1 cells with rWUPyV was passaged three times. 
In the first passage, an increase in viral DNA of approximately one log was detected between 
two and 96 hpi (Figure 4.8). Figure 4.8 shows data from both the initial infection (also seen in 
Figure 4.7) and the first passage for comparison. By passage two, only trace amounts of viral 
DNA remained, and none was detectable by passage three (not shown).  
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Table 4.2. Results of infections of immortal cell lines with rWUPyV.  
Cell line Cell type Results 
A549 Adenocarcinomic alveolar basal epithelials No replication 
MRC-5 Normal lung fibroblasts No replication 
WI-38 Normal lung fibroblasts No replication 
Calu-3 Adenocarcinomic bronchial epithelials No replication 
Hs 198.Ton Normal tonsil fibroblasts No replication 
BEAS-2B Normal lung/bronchial epithelials No replication 
H820 Adenocarcinomic lung/lymph node epithelials No replication 
KG-1a Myeloid lineage (promyeloblast)* No replication 
KG-1 Myeloid lineage (myeloblast)* Inconclusive 
THP-1 Myeloid lineage (monocyte)* Inconclusive 
U-937 Myeloid lineage (monocyte)* Inconclusive 
HL-60 Myeloid lineage (myeloblast)* Inconclusive 
*All myeloid lineage cell lines were derived from cells from leukemias or lymphomas. 
 
Figure 4.7. Viral DNA detected in supernatants from immortal cell lines following infection 
with rWUPyV at a MOI of ~100. Two replicates were performed for each cell type. 
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Figure 4.8. Passage of rWUPyV-infected THP-1 cell lysates into fresh THP-1 cells. An increase 
in viral DNA is seen during the initial infection (same data as Figure 4.7) and upon passage. 
 
 
Having demonstrated that the increase in viral DNA in the supernatant following 
infection of THP-1 cells was reproducible and sustained through passage, we next sought to 
determine if viral DNA also increased inside the cells. THP-1 cells in a T75 flask were infected 
with rWUPyV. Aliquots of the suspension cells were taken at two, 24, 72 and 120 hpi, and the 
cells and supernatant were separated. DNA, RNA and protein were extracted from the cells. No 
WUPyV protein was seen by Western blot (not shown). While viral DNA increased in the 
supernatant, a steady decrease was seen in the cells (Figure 4.9a). RNA was used to assess 
whether splicing of viral transcripts was occurring. Both the WUPyV small T antigen (STAg) 
and large T antigen (LTAg) are spliced, and the splice products should only be detectable if an 
infection was initiated (Figure 4.9b).  
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Figure 4.9. Viral nucleic acid produced from a rWUPyV infection of THP-1 cells. (A) Viral 
DNA present in THP-1 cells and their supernatant following infection. (B) Schematic of RNA 
splicing in WUPyV. (C) RT-PCR of RNA from THP-1 cells. NTC, no template control. 
 
  
The early pre-mRNA was detected in all four time points (0, 24, 72 and 120 hpi). There 
was also a LTAg splice product at 0 hpi, but no band was seen in the later time points. No STAg 
splice product was seen. All three bands were detected in RNA extracted from a whole genome 
(cWUPyV) transfection of cells (lane six), as expected. The zero hpi time point was actually 
taken two hours after the infection was initiated, so it was possible RNA transcripts were 
generated. Alternatively, the band could be carry over from the input rWUPyV lysate, which is 
known to contain the splice products. 
 Although an increase in viral DNA was reproducibly seen by 24 hpi in THP-1 cells 
infected with rWUPyV, no spliced RNA transcripts were seen in the later time points. One 
hypothesis was that a very small number of cells were infected.; there was enough virus made 
during the initial infection to initiate a new infection in the first passage, but by the second 
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passage, the virus was too dilute. An approximate MOI of 100 was used for the aforementioned 
infections. However, this number is based on the genome copies calculated from qPCR analysis 
of DNase treated lysate, which cannot differentiate between infectious and defective particles. To 
test our hypothesis, we infected THP-1 cells in duplicate with increasing amounts of virus at 
dilutions of 1:1000 (MOI ~560), 1:100 (MOI ~5600) and 1:10 (MOI ~56,000). We also included 
a third antibody against IFNβ to further block the innate immune response, and all three 
antibodies were included in the media pre-infection and for the duration of the experiment. 
Supernatant was collected at zero, 24, 48, 72 and 96 hpi. Cells were collected at 96 hpi. RNA 
was extracted from half of the cells, while the remainder was prepared for electron microscopy.  
No viral particles were seen in either the cells or the supernatant. However, viral DNA 
increased steadily from zero to 24 hpi in the two most concentrated dilutions (1:10, 1:100) before 
plateauing (1:10) or decreasing (1:100) (Figure 4.10a). In cells infected with the lowest 
concentration of rWUPyV (1:1000), an initial increase in viral DNA was seen in the first 24 hpi, 
but one replicate subsequently plateaued, while the other decreased at 48 hpi, increased again by 
72 hpi and then plateaued. LTAg spliced transcripts were detected in all three samples (Figure 
4.10b). No STAg spliced transcript was seen. While the RT-PCR of the DNA plasmid control 
yielded the expected band at 571 bp, it is unclear why we did not detect the pre-mRNA in RNA 
extracted from cells transfected with the WUPyV early region, although it was expected.  
A portion of the cells from this THP-1 infection was passaged three times (every 3-5 
days) into fresh media. DNA and RNA were extracted from cells immediately before passage for 
qPCR and RT-PCR analysis. Viral DNA decreased steadily over the three passages (Figure 
4.11a). No STAg splice product was seen, but LTAg spliced transcripts were detected in both 
samples from the 1:10 dilution infection in passage one (wells A and D, lanes 2 and 5) (Figure 
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4.11b). The LTAg splice band was also present in the input, so it was possible the product in 
wells A and D is carry over from the inoculum. An early pre-mRNA band at 571 bp was visible 
in several lanes, but no specific pattern was evident. Again, the WUPyV early region control did 
not yield all three bands as was expected. It is unclear why this occurred.  
 
Figure 4.10. Infection of THP-1 cells with varying concentration of rWUPyV. (A) Viral DNA 
detected in THP-1 cells post-infection. (B) RT-PCR of RNA from THP-1 cells at 96 hpi. NTC, 
no template control.
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Figure 4.11. Passage of THP-1 cells infected with rWUPyV. (A) Viral DNA detected at the end 
of each passage. (B) RT-PCR of RNA from THP-1 cells at the end of each passage. NTC, no 
template control. 
 
 
 
DISCUSSION 
 We attempted to establish a cell culture system for WUPyV in two primary human cell 
lines and in 12 immortal cell lines. While infection of four monocytic cell lines showed initial 
promising results, later experiments using THP-1 cells were inconclusive. Viral DNA increased 
over the first 24 hpi, after which levels either plateaued or decreased. This effect was also seen 
upon passage of lysate onto fresh cells. Despite these promising results, no viral protein was 
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detected by Western blot, and no virions were seen in the supernatants or in the cells by electron 
microscopy. Analysis of RNA splicing showed LTAg spliced transcripts at 96 hpi, although 
splicing was not seen in most samples from later passages. While we were not able to establish a 
system for robust culture of WUPyV, our work will serve as a solid foundation on which to base 
future attempts. 
 One explanation for these results is that infection is occurring in a very small portion of 
cells. Less sensitive means of measuring infection, such as electron microscopy or Western blot, 
likely would not have been able to detect virus produced at low levels. However, this would not 
explain why spliced viral transcripts were absent at later time points. We attempted to boost viral 
infection by adding an additional antibody against IFNβ and increasing the MOI of the inoculum. 
This did seem to have an effect on viral titers, as viral DNA plateaued instead of steadily 
decreasing, and spliced transcripts were seen at 96 hpi. Despite these effects, spliced transcripts 
were not consistently detected in the cells upon passage. If cells were infected at a higher but still 
relatively low rate, dilution of the cells by passaging may have negated the initial gains. 
 Future attempts to culture WUPyV should build on the results presented here. It may be 
useful to attempt infections of other cell lines, including other types of primary respiratory 
epithelial cells. It is currently debated whether pneumocytes can be grown in cell culture, but this 
could be a better option in the future. It may be advisable to attempt other means of knocking 
down the immune system. However, it is important to note that polyomavirus infections typically 
require the cells to be dividing, and growth can often be impeded by impairing innate immunity. 
 In conclusion, we were not able to establish a cell culture system for WUPyV. However, 
our data suggests other respiratory or monocytic cell lines may support growth of WUPyV. 
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OVERVIEW 
Two broad questions guided the research described in this dissertation:  “Are there additional 
novel polyomaviruses infecting humans?” and “Do these polyomaviruses cause disease in their 
human hosts?” In the Introduction, I argued why I believe these questions are important to 
address, and the research presented in Chapters 2-4 detailed some initial answers. Here, I 
summarize these and offer some suggestions for future directions. 
 
SECTION I:  Are there additional, novel polyomaviruses infecting humans? 
 The easy answer to this question today is yes, of course, there are novel polyomaviruses 
infecting humans. However, prior to 2007, the answer would have been vastly different. The first 
two human polyomaviruses, JC and BK polyomaviruses (JCPyV, BKPyV, respectively) were 
both discovered in the 1970s, and no new additional human polyomaviruses were discovered 
until 2007. In 2006, discovering new polyomaviruses was not likely a goal of any research 
group, and most human polyomavirus research focused on studying the biology and pathogenesis 
of JCPyV and BKPyV. The intervening years also saw phenomenal discoveries in basic biology 
using the polyomaviruses SV40 and murine polyomavirus (MPyV). However, the discoveries of 
WU and KI polyomaviruses (WUPyV, KIPyV, respectively) in 2007 (1, 2) reinvigorated the 
field, and several groups began looking for new polyomaviruses. With the subsequent 
discoveries of Merkel cell carcinoma polyomavirus (MCPyV) (3) and Trichodysplasia spinulosa-
associated polyomavirus (TSPyV) (4) and their associations with Merkel cell carcinoma (MCC) 
and Trichodysplasia spinulosa, respectively, interest in polyomaviruses, particularly MCPyV, 
increased substantially. Previous research showed polyomaviruses were strongly associated with 
various animal cancers; JCPyV and BKPyV were weakly associated with human cancers; and 
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their proteins displayed oncogenic properties in vitro. However, MCPyV was the first human 
polyomavirus to be strongly associated with a human cancer and was found clonally integrated 
into a large proportion of MCCs (3). This finding greatly increased interest in the role of 
polyomaviruses in human cancer and in additional oncogenic polyomaviruses that may exist. 
Taken together, the discoveries of these viruses brought more researchers to the field and 
broadened interest in polyomavirus biology and discovery. 
Prior to the work described here, nine human polyomaviruses had been discovered, 
including those previously mentioned and human polyomavirus 6 (HPyV6) (5), human 
polyomavirus 7 (HPyV7) (5) and human polyomavirus 9 (HPyV9) (6). Shortly after our report 
describing the discovery of MWPyV (Chapter 2), two others groups published very closely 
related novel polyomaviruses, which ultimately turned out to be strains of MWPyV (Table 5.1). 
The first group, Buck, et al., described human polyomavirus 10 (HPyV10) in an anal wart from a 
person with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome, 
a rare genetic disorder (7). No other samples were tested for HPyV10. This virus was 95-99% 
identical to MWPyV, depending to which MWPyV stain it was compared. The authors argued 
that the discovery of abundant levels of HPyV10 within the wart indicated the virus was not a 
contaminant but was instead a bona fide human virus. The second group, Yu, et al., detailed the 
discovery of MX polyomavirus (MXPyV) in pediatric stool samples (8). MXPyV was 
subsequently detected in 28 of 834 (3.4%) stool samples from children in California, Mexico and 
Chile and in one respiratory sample (out of 136) from a child in Mexico. The virus was not found 
in urine and blood samples from immunocompromised patients from California. The authors also 
performed a case-control study to examine whether MXPyV was associated with diarrhea, 
although no association was found. As with MWPyV, one patient had multiple samples over a 
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span of several months (91 days) that were positive for MXPyV. The virus was 99.8% identical 
to the MWPyV St. Louis strain.  
 
Table 5.1. Summary of MWPyV studies to date. 
Study (year) Cohort Samples MWPyV-positive 
Siebrasse, et al. (2012) (9) Children with diarrhea 514 stools 12 (2.3%) 
Buck, et al. (2012) (7) Adult with WHIM  1 anal wart 1 (100.0%) 
Yu, et al. (2012) (8) 
Children with diarrhea 96 stools 12 (12.5%) 
Children with respiratory infection 136 nasal washes 1 (0.7%) 
Children with or without diarrhea 546 stools 18 (3.3%) 
Transplant recipients 
193 plasmas 0 (0.0%) 
287 plasmas/urines 0 (0.0%) 
Children with diarrhea 96 stools 0 (0.0%) 
Healthy children 96 stools 4 (4.2%) 
Lim, et al. (2012) (10) 
Adult renal transplant recipients 
237 stools 0 (0.0%) 
261 plasmas 0 (0.0%) 
261 NPAs 0 (0.0%) 
373 urines 0 (0.0%) 
Children with diarrhea 332 stools 5 (1.5%) 
Healthy children 390 stools 5 (1.3%) 
Rockett, et al. (2013) (11) 
Patients with respiratory symptoms 1232 respiratory* 18 (1.5%) † 
Healthy children 153 respiratory* 14 (9.2%) 
Symptomatic patients (undefined) 161 bloods 0 (0.0%) 
Symptomatic patients (undefined) 171 CSFs 0 (0.0%) 
Symptomatic patients (undefined) 189 urines 0 (0.0%) 
Symptomatic patients (undefined) 185 stools 9 (4.9%) 
Healthy children 78 stools 10 (12.8%) 
Li, et al. (2013) (12) 
Children with diarrhea 211 stools 3 (1.4%) 
Healthy children 208 stools 6 (2.9%) 
Ramqvist, et al. (2014) (13) Adults with mucosal melanoma 
37 mucosal 
melanomas 
0 (0.0%) 
Wieland, et al. (2014) (14) 
HIV-positive men 205 skin swabs 19 (9.3%) 
HIV-negative men 238 skin swabs 8 (3.4%) 
* Respiratory samples included NPAs, BALs, nose and throat swabs, bronchial washes, sputum and lung tissues. 
† All MWPyV-positive samples were from children. 
 
 
In addition to these two discovery reports, at least five other MWPyV prevalence studies 
have been published (Table 5.1). MWPyV was not found in any of the adult samples (stool, 
plasma, urine and nasopharyngeal aspirates (NPA)) that Lim, et al. tested (10). While MWPyV 
was found in pediatric stool specimens, there was no difference between the prevalence in cases 
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versus controls. Rockett, et al. found MWPyV in respiratory and stool samples (11). The 
respiratory samples were taken from healthy children (9.2% positive) and children with 
respiratory tract infections (1.5%). The stool samples also came from healthy children (12.8%) 
and children with gastrointestinal illness (4.9%). All MWPyV-positive samples were obtained 
from children less than 10-years-old; samples from adults were tested but were negative. Four of 
the positive samples came from immunocompromised patients diagnosed with acute 
lymphoblastic leukemia. A number of these samples were co-infected with other viruses. One 
patient had multiple positive samples over a period of five days. Finally, MWPyV was more 
likely to be found in healthy, younger children (less than five-years-old) than in older children or 
in children with respiratory or gastrointestinal symptoms. Ramqvist, et al. tested 37 mucosal 
melanoma samples for MWPyV, all of which were negative (13). Wieland, et al. tested 443 
forehead skin swabs from HIV-positive or HIV-negative men and found the virus significantly 
more frequently in the HIV-positive patients (9.3% versus 3.4%) (14). Finally, Li, et. al. 
conducted a case-control study of fecal samples from children with diarrhea and found no 
difference in MWPyV prevalence between the cases and controls (12).  
These other MWPyV reports both corroborate and expand work presented in Chapter 2. 
Multiple reports found the virus in samples from the respiratory and gastrointestinal tracts (7-12). 
One report also described detection of the virus on the skin (14). Despite collective testing of 
over 700 plasmas and 700 urines, MWPyV was not detected (8, 10, 11). The virus was also not 
detected in mucosal melanomas or cerebrospinal fluid (CSF) (11, 13). Consistent with the initial 
findings in Chapter 2, MWPyV was predominantly detected in children. Yu, et al. tested 480 
plasma and urine samples from adult transplant recipients; Rockett, et al. tested hundreds of 
various specimen types from adults; and the Lim, et al. study tested 1,132 samples (plasma, 
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urine, stool and NPA) from adult kidney transplant recipients. All were negative. The only adult 
samples that were positive for MWPyV were skin swabs from adult men in the Wieland study. 
Many of the adult specimens were from immunocompromised transplant recipients, who would 
be expected to have an increased risk of polyomavirus infection given their immune status. It is 
unclear why children seem more susceptible to infection with these viruses. Other human 
polyomaviruses are typically acquired in childhood, so our detection of the virus in this 
population may represent shedding during its initial infection. Perhaps MWPyV does not often 
reactivate in adults, even in those with compromised immune systems.  
 
Figure 5.1.  Global distribution of MWPyV. Blue (Gregory Storch, unpublished data), red (9), 
green (8), purple (7), orange (10), light blue (14), yellow (11) and pink (12). 
 
 
Since the initial discovery of MWPyV, strains of the virus have been detected globally 
(Figure 5.1). Data described in Chapter 2 found the virus in Malawi and in the United States (St. 
Louis). Subsequent work from our lab and others detected the virus in Washington, Maryland, 
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California, Mexico, Chile, The Gambia, China, Germany and Australia (see Figure 5.1 for 
references). Given the global distribution of the virus and its detection within a wart, it seems 
unlikely that the virus is a dietary contaminant. In addition, both our study (Chapter 2), the 
MXPyV study and Rockett, et al. found patients with multiple samples positive for the virus over 
several months. This likely represented chronic shedding of the virus rather than re-infection. 
As with the discovery of any novel virus, there are many outstanding questions regarding 
MWPyV. First, does MWPyV infect humans? The data we already have, including the chronic 
shedding, global distribution and discovery of HPyV10 within a wart, suggests that it does. 
However, seroprevalence studies represent the best way to definitively demonstrate that MWPyV 
infects humans. This type of study can also determine the percentage and age distribution of the 
population that is infected, among other things. Other groups are currently pursuing this line of 
research. Second, what is the prevalence of MWPyV? While the seroprevalence of most 
polyomaviruses is quite high, the prevalence of viral DNA is typically quite low (<10%), so we 
would expect MWPyV to be similarly low. Studies have so far supported this hypothesis, with 
our study demonstrating a prevalence of 2.3% in stool samples and other studies having similarly 
low rates in stool and respiratory specimens. Additional studies with larger cohorts in different 
locals will be important to answering this question. Third, what is the tropism of MWPyV? As 
previously discussed, the virus has predominantly been detected in stool and respiratory samples. 
However, few samples from other body sites have been tested, and no specimens from other sites 
have been obtained from pediatric patients. Given the significantly higher prevalence of the virus 
in children, it will be important to test pediatric specimens in the future. If the virus is a resident 
of the gastrointestinal tract, it does not necessarily mean it causes disease there, although it 
could. It may be that the virus infects humans but is not pathogenic. Alternatively, the virus may 
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cause disease elsewhere in the body and be shed in the stool as a byproduct. For example, 
poliovirus is shed in and spread through feces but causes disease in the nervous system. In 
addition to detection of viral nucleic acids, as has been done in the past, future studies should 
also determine where in the body viral proteins can be detected (similar to experiments described 
in Chapter 3 for WUPyV and KIPyV).  
While many more questions about MWPyV exist, perhaps the most important one is 
“Does MWPyV cause disease in humans?” While answering the earlier questions will provide 
useful information toward this end, answering this particular question directly is difficult. As 
mentioned in the introduction, the gold standard approach to determining disease causality is 
fulfillment of Koch’s postulates. However, this either requires human volunteers, which is not 
ethical given the uncertain pathogenicity of this virus, or growth of the virus in culture. We have 
not yet attempted to grow MWPyV in culture, although we would expect to encounter similar 
difficulties as those noted for WUPyV. Despite this hurdle, growth of MWPyV in culture would 
represent a major advance and should be attempted in the future. As with WUPyV, defining the 
virus’ tropism in the human body could inform selection of cell lines in which to attempt 
growing the virus. Another approach to addressing this question is the case-control study. Five 
such studies have been performed for MWPyV. None of the studies found an association 
between MWPyV and diarrhea (8, 10, 12) or between MWPyV and respiratory illness (11). 
However, MWPyV was found more frequently in skin samples from patients with HIV (14).  
Following the discovery of MWPyV, three additional polyomaviruses were discovered in 
humans. STL polyomavirus (STLPyV) was also discovered in a stool sample from a child from 
Malawi and detected in the United States (St. Louis) and the Gambia (10). The virus was most 
closely related to MWPyV, and phylogenetic analysis demonstrated the viruses share an 
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ancestral recombinant origin. The STLPyV early region was alternatively spliced to yield a new 
form of T antigen designated 229T. Human polyomavirus 12 (HPyV12) was discovered in 
resected human liver tissue and subsequently detected in cecum and rectal tissues and a stool 
sample (15). It was not closely related to any known polyomavirus, and its seroprevalence rate 
was 17-23% depending on the cohort. Finally, New Jersey polyomavirus (NJPyV) was 
discovered in a muscle biopsy from a pancreatic transplant recipient who developed weakness, 
retinal blindness and necrotic plaques (16). Viral particles consistent with polyomavirus were 
visible by electron microscopy. In situ hybridization specific for NJPyV was also positive. Both 
viral particles and viral DNA were detected within vascular endothelial cells.  
Collectively, these discoveries show the number of polyomaviruses is continuing to 
increase rapidly. It is likely that new polyomaviruses will continue to be discovered as molecular 
techniques, including high throughput sequencing, expand and are applied to more and more 
specimens. MWPyV and STLPyV were both discovered in specimens originally collected for a 
different study. As high throughput sequencing is now being applied to a myriad of specimens 
from all over the world, applying the viral discovery techniques mentioned in the Introduction to 
this existing data would likely yield numerous new viruses. 
 
SECTION II:  Do these polyomaviruses cause disease in their human hosts? 
 Again, the obvious answer to this question is yes, it is likely at least some of the new 
polyomaviruses cause disease in humans. However, this dissertation focuses on three of the new 
polyomaviruses, MWPyV, WUPyV and KIPyV. MWPyV has already been discussed in Section 
I, so the focus of this section will be the latter two viruses. We took two approaches to this 
question. The first approach was to establish a cell culture system for WUPyV. This system 
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would be used to study viral biology and as a step toward fulfilling Koch’s postulates. As 
mentioned in the Introduction, the gold standard approach for establishing disease causality is the 
fulfillment of Koch’s postulates, which require the virus to be grown in culture. Others have 
proposed alternatives to these criteria, including Stanley Falkow’s Molecular Koch’s postulates 
(17) and a similar revised version of Koch’s from David Fredricks and David Relman (18). 
While neither of the two more recent criteria require the virus to be grown in culture, others have 
noted how establishment of a cell culture system for WUPyV is a chief requirement for studying 
the virus’ molecular biology (19). We were ultimately unsuccessful at establishing a cell culture 
system for WUPyV, but our work should lay the groundwork for future attempts. 
 It is unclear why our attempts were unsuccessful. As noted in the discussion for Chapter 
4, it is possible that very few cells were infected, and the infection was diluted further upon 
passage. Alternatively, host factors necessary for later stages of the viral life cycle may not be 
present. Monocytic cells produce a potent innate immune response, which could also have 
inhibited viral growth. It is also unclear why the WUPyV replication system only supports one 
round of replication. One hypothesis is that Vero cells do not express the WUPyV entry receptor. 
Alternatively, perhaps host factors necessary for release of intact, infectious particles into the 
supernatant are not present. While this is not an exhaustive list of potential hypotheses, they 
represent avenues for additional research. In addition, future attempts should expand the list of 
cell lines to infect to include other primary respiratory cells and additional monocytic cell lines. 
 The second approach we took was to determine the cell and tissue tropism of WUPyV 
and KIPyV in vivo in the human host. This is considered one of the most pressing research 
questions concerning the newer human polyomaviruses. Prior to our work, neither virus had been 
detected in specific cell types or tissues. Numerous studies, which are summarized in Table 4.1, 
121 
 
using nucleic acid-based methods detected both viruses in a variety of specimen types, but these 
methods did not allow detection of the viruses in single cells. In addition, most samples were 
body fluids, not tissues. Data presented in Chapter 3 is the first identification of specific 
WUPyV- and KIPyV-positive cell types. We also reported the first visualization of putative 
WUPyV viral particles in a human lung. A summary of these findings can be found in Table 3.2, 
but in brief, WUPyV and KIPyV VP1 proteins were both detected in alveolar macrophages 
within human lungs. WUPyV protein was also detected within respiratory epithelial cells and in 
close association with mucin-producing cells in the trachea. Finally, KIPyV protein was also 
detected within splenic cells. We tested a number of tissues that were negative for the viruses, 
which will help narrow future tropism studies. There were additional cell types positive for the 
viruses, which we were ultimately unable to identify. If patient cases positive by PCR for 
WUPyV or KIPyV are described in the future, applying the new immunohistochemical assays 
described in Chapter 3 will hopefully identify these additional cell types.  
 Future research should also focus on the potential pathogenesis of WUPyV and KIPyV in 
the lung. In two cases presented in Chapter 3, patients with acute respiratory illness that were 
positive for WUPyV or KIPyV later died. In both cases, viral or bacterial causes for the deaths 
were not identified, although both were thought to be of infectious etiology. The size and 
morphology of the viral particles found in the lungs of one of these patients was consistent with 
polyomavirus. While it is impossible to prove causality in either of these cases, they are the 
strongest evidence to date that WUPyV and KIPyV may be human pathogens.  
KIPyV was also detected in a second case of an HIV-positive man. In this case, virus was 
found in a number of cells within both the lung and the spleen. One hypothesis for this is that the 
virus entered via the respiratory route and spread through the blood to the spleen. This 
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hypothesis is consistent with the second KIPyV case, where virus was only detected in the lung. 
Although both patients were immunocompromised, perhaps the HIV-positive patient’s immune 
system was less capable of controlling the KIPyV infection. This case gives us insight into the 
potential pathogenesis and spread of KIPyV within the human host. 
Finally, it is important to note that all the cases described in Chapter 3 were of 
immunocompromised patients. JCPyV and BKPyV both cause disease exclusively in 
immunocompromised patients, and MCPyV and TSPyV are also thought to follow this 
paradigm. Given our data, it seems reasonable to conclude that WUPyV and KIPyV may also 
cause disease only in immunosuppressed individuals. However, there is some amount of 
selection bias in our cases. Studies on WUPyV and KIPyV have tended to focus on 
immunosuppressed patients, and we did not test any immunocompetent cases. Immunocompetent 
patients are not routinely screened for the human polyomaviruses, so it is unlikely we would 
identify cases in this patient group unless they died of acute respiratory disease of unknown 
etiology.  
To our knowledge, no additional studies of WUPyV or KIPyV tropism have been or are 
being performed. However, additional studies to establish a cell culture system, identify the 
remaining virus-positive cell types and further explore potential viral pathogenicity will be 
important toward answering the question of disease causality. In addition to the approaches we 
used here, other complementary approaches could be taken. While some case-control studies of 
WUPyV and KIPyV have already been performed, future studies should be narrowed to explore 
the role of these viruses in acute respiratory illness, particularly in immunocompromised 
individuals. We described the first electron microscopy of putative WUPyV particles. As it is 
difficult to perform electron microscopy on formalin-fixed, paraffin-embedded tissues, applying 
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this technique in combination with immunogold labelling to fresh tissue in cases of acute 
respiratory illness could provide more concrete evidence of the specific infecting virus. 
Overall, the case for WUPyV and KIPyV being human pathogens is growing. Both have 
been detected in a variety of specimen types obtained from humans around the world. The 
majority of the population is infected with both viruses, with infection likely occurring in 
childhood. Both viruses can be detected in the lungs of immunocompromised patients with 
severe respiratory illness, and in at least one case, KIPyV appears to have spread outside the 
respiratory tract to the spleen. Finally, putative WUPyV particles were also detected within the 
lungs. All of this data is consistent with the viruses being pathogens, although none of it is 
conclusive. Future work as outlined above will be critical to answering the question of whether 
these viruses are human pathogens. 
 
FINAL CONCLUSIONS 
 The work described in the preceding three chapters has expanded our understanding of 
the Polyomaviridae family. The addition of a tenth member to the family and the detection of 
WUPyV and KIPyV in specific cell and tissue types  represent contributions to the field that will 
hopefully influence future work on these viruses.  
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ABSTRACT 
Immunocompromised patients are at risk for disease caused by infection by some 
polyomaviruses. To define the prevalence of polyomaviruses in children undergoing 
transplantation, we collected samples from a longitudinal cohort and tested for the nine known 
human polyomaviruses. All were detected; several were present in previously unreported 
specimen types. 
 
INTRODUCTION 
BK and JC polyomaviruses (BKPyV, JCPyV) cause disease in immunocompromised 
persons. Both are double-stranded DNA viruses in the family Polyomaviridae. Seven additional 
human polyomaviruses were discovered during 2007–2011: KI polyomavirus (KIPyV) (1), WU 
polyomavirus (WUPyV) (2), Merkel cell polyomavirus (MCPyV) (3), human polyomavirus 6 
(HPyV6) (4), human polyomavirus 7 (HPyV7) (4), Trichodysplasia spinulosa-associated 
polyomavirus (TSPyV) (5), and human polyomavirus 9 (HPyV9) (6). 
The seven novel polyomaviruses have been detected in various specimen types; detection 
has been extensively reviewed for KIPyV, WUPyV, and MCPyV (7). Polyomaviruses HPyV6, 
HPyV7, TSPyV, and HPyV9 have been detected in skin (4, 5, 8); TSPyV and HPyV9 have also 
been detected in urine, and HPyV9 was detected in serum (6). However, only two of these 
recently identified viruses have been specifically implicated in human diseases; MCPyV is 
associated with Merkel cell carcinoma (3), and TSPyV has been linked to Trichodysplasia 
spinulosa (5). Immunosuppression is a likely cofactor in both diseases. The potential 
pathogenicity of the other five novel polyomaviruses is unknown. As a first step toward 
exploring their disease potential, we sought to define their prevalence in immunocompromised 
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transplant recipients. To this end, we established a longitudinal cohort of children undergoing 
transplantation at St. Louis Children’s Hospital, St. Louis, Missouri, USA. 
 
THE STUDY 
We recruited 32 patients who were scheduled to receive transplants (two lung, 11 liver, 
five heart, two kidney, one liver/lung, and 11 bone marrow transplants) during October 2008–
April 2010. The Human Research Protection Office of Washington University in St. Louis 
approved this study. The mean age of enrolled patients was 5.8 years, and the median age was 
3.1 years. Thirty patients received transplants and were studied for one year after transplantation. 
We collected 716 clinical specimens (160 nasopharyngeal swab, 169 urine, 122 fecal, 265 
plasma) during 265 patient visits. We collected 298 specimens from patients during symptomatic 
episodes, which were defined as having more than one of the following: fever, respiratory 
symptoms, or gastrointestinal symptoms. We collected clinical data using a questionnaire and the 
medical records. 
Fecal material was diluted 1:6 in phosphate-buffered saline and filtered through 0.45-μm 
membranes. For all specimens, we extracted total nucleic acids using an Ampliprep Cobas 
extractor (Roche). We used published real-time PCRs for WUPyV (9), KIPyV (9), TSPyV (5), 
MCPyV (10), BKPyV (11), and JCPyV (12) (Table 1). We developed assays for HPyV6, 
HPyV7, and HPyV9 using Primer Express software (Applied Biosystems) (Table 1). To assess 
the performance of each assay, we used serial dilutions (5 to 5x10
6
 copies/reaction) of a plasmid 
containing the target sequence. All three assays demonstrated a sensitivity of approximately five 
copies/reaction and yielded linear curves with R
2
 values >0.99. 
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Table 1. Real-time PCR assays to detect human polyomaviruses in children undergoing 
transplants, United States, 2008–2010. NCCR, non-coding control region; LTAg, large T 
antigen. 
Virus Target Primers Probe 
WUPyV NCCR 
WU-C-4824-F: GGCACGGCGCCAACT 
WU-C-4861-TM: 5'-FAM-
TGCCATACCAACACAGCTGCTGAGC-TAMRA-3' WU-C-4898-R: 
CCTGTTGTAGGCCTTACTTACCTGTA 
KIPyV LTAg 
KI-B-4603-F: GAATGCATTGGCATTCGTGA 
KI-B-4632-TM:  5'-FAM-
TGTAGCCATGAATGCATACATCCCACTGC-TAMRA-3' KI-B-4668-R: 
GCTGCAATAAGTTTAGATTAGTTGGTGC 
TSPyV LTAg 
LTF: TGTGTTTGGAAACCAGAATCATTTG LTP:  5'-FAM-
TTCTTCTTCCTCCTCATCCTCCACCTCAAT-TAMRA-3' LTR: TGCTACCTTGCTATTAAATGTGGAG 
MCPyV LTAg 
LT.1F: CCACAGCCAGAGCTCTTCCT LT probe:  5'-FAM-TCCTTCTCAGCGTCCCAGGCTTCA-
TAMRA-3' LT.1R: TGGTGGTCTCCTCTCTGCTACTG 
HPyV6 VP1 
ES011F: GCCTGGAAGGGCCTAGTAAAG ES024: 5'-FAM-
ACCAACCATCTGTTGCAGGCATTAAAGCTA-TAMRA-3' ES012R: ATTGGCAGCTGTAACTTGTTTTCTG 
HPyV7 VP1 
ES017F: GGTCCAGGCAATACTGATGTAGCTA ES025:  5'-FAM-
CCTGCAAGCCCTCAGAAAGCAAGTAAATG-TAMRA-3' ES018R: TCTGCAACCCAGAGCTCTACTG 
HPyV9 LTAg 
ES026F: GAAGACCCTGATCCTGAGGAAGA 
ES031: 5'-FAM-
TGGATCATCCCAGAGTTCATTTACCTGCA-TAMRA-3' ES027R: CTCTGGAGTATTAGGTTCAGGCTTCT 
BKPyV LTAg 
BK-Deg-F: AGCAGGCAAGRGTTCTATTACTAAAT Bk-Deg-P: 5'-FAM-
AAGACCCTAAAGACTTTCCYTCTGATCTACACCAGTTT-
TAMRA-3' BK-Deg-R: GARGCAACAGCAGATTCYCAACA 
JCPyV VP2/3 
JL1 (F): AAGGGAGGGAACCTATATTTCTTTTG JL1 (P): 5'-FAM-
CTCATACACCCAAAGTATAGATGATGCAGACAGCA-
TAMRA-3' 
JL1 (R): TCTAGCCTTTGGGTAACTTCTTGAA 
 
Each of the 25-μl quantitative PCRs included 5 μL of extracted sample, 12.5 pmol of 
each primer, and 4 pmol of probe. The MCPyV primers and probe were used as described (10). 
We tested samples in a 96-well plate format, with eight water negative controls and one positive 
control/plate. Reactions were cycled as recommended using either an ABI 7500 real-time 
thermocycler (Applied Biosystems) or a CFX96 real-time thermocycler (BioRad). The threshold 
of all plates was set at a standard value, and samples were counted as positive if their cycle 
threshold was <37.00. 
All 716 specimens were tested for each virus (Table 2). The most frequently detected 
virus was BKPyV, which was found primarily in urine as expected. JCPyV was detected in one 
130 
 
plasma sample. HPyV6, HPyV7, MCPyV, and TSPyV were detected in specimen types not 
previously reported. HPyV6 and TSPyV were detected in fecal samples and nasopharyngeal 
swab samples, and HPyV7 was detected in a nasopharyngeal swab and urine. One fecal sample 
was positive for MCPyV. Because HPyV6, HPyV7, and MCPyV have been previously detected 
in skin, we cannot rule out the possibility that their presence in specimens could have been 
caused by shedding from skin. 
 
Table 2. Polyomaviruses detected among specimens from children undergoing transplants, 
United States, 2008–2010. Ct, cycle threshold; ID, identification; BMT, bone marrow transplant; 
NP, nasopharyngeal; 
Virus Specimen type Transplant Ct Patient ID Additional information 
HPyV6 Stool BMT 32.19 3011 6/6/10, 1mo post-transplant 
HPyV6 NP Heart 36.13 4005 11/25/10, 7mo post-transplant 
HPyV6 Stool Lung 36.95 5001 8/17/10, 1mo post-transplant 
HPyV7 NP Liver 34.57 1002 6/16/09, 7mo post-transplant 
HPyV7 Urine Liver 36.54 1002 7/15/09, 8mo post-transplant 
HPyV9 Urine Liver 36.72 1009 2/09/10, 1wk post-transplant 
KIPyV NP BMT 16.28 3001 7/7/09, 3mo post-transplant 
KIPyV NP BMT 36.07 3001 5/19/09, 1mo post-transplant 
KIPyV NP BMT 33.37 3008 11/12/09, pre-transplant 
KIPyV NP BMT 31.04 3009 7/30/10, 6mo post-transplant 
MCPyV NP BMT 36.29 3011 4/15/10, pre-transplant 
MCPyV Stool BMT 34.56 3011 7/2/10, 2mo post-transplant 
TSPyV NP Heart 32.98 4001 5/29/09, 1wk post-transplant 
TSPyV NP Heart 30.74 4001 6/18/09, 1mo post-transplant 
TSPyV Stool Heart 33.89 4001 5/29/09, 1wk post-transplant 
WUPyV NP BMT 36.62 3005 7/15/09, pre-transplant 
WUPyV NP BMT 28.81 3007 11/6/09, 2mo post-transplant 
JCPyV Plasma BMT 36.12 3011 8/24/10, 3mo post-transplant 
BKPyV Urine BMT 15.83 3010 4/15/10, 1mo post-transplant 
BKPyV Urine Kidney 36.67 2022 7/1/10, 10mo post-transplant 
BKPyV Urine BMT 30.80 3011 8/24/10, 3mo post-transplant 
BKPyV Urine Heart 25.84 4001 8/14/09, 2mo post-transplant 
BKPyV Urine Heart 35.89 4003 12/23/09, 2mo post-transplant 
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BKPyV Urine Heart 24.37 4001 9/23/09, 4mo post-transplant 
BKPyV Urine Liver 28.56 1010 11/23/09, 1wk post-transplant 
BKPyV Urine Lung 33.13 5002 5/3/11, 1 year post-transplant 
BKPyV Urine Lung 25.25 5002 2/8/11, 10mo post-transplant 
BKPyV Urine Kidney 9.97 2002 3/4/10, 6mo post-transplant 
BKPyV Urine BMT 30.10 3009 3/5/10, 2mo post-transplant 
BKPyV Urine Liver 22.89 1001 1/7/09, 3mo post-transplant 
BKPyV Urine Kidney 34.41 2002 5/13/10, 8mo post-transplant 
BKPyV NP Kidney 35.93 2002 3/4/10, 6mo post-transplant 
BKPyV Stool Kidney 33.15 2002 3/4/10, 6mo post-transplant 
BKPyV Stool Liver 33.33 1001 12/18/08, 2mo post-transplant 
BKPyV Stool Liver 34.84 1001 1/7/09, 3mo post-transplant 
 
 We collected two serial nasopharyngeal samples that were positive for KIPyV from 
patient 3001 (Table 2), a one-year-old child who had received a bone marrow transplant as 
treatment for Fanconi anemia. The first sample, a nasopharyngeal swab obtained one month after 
transplant, had low levels of KIPyV. To determine the viral load of the second nasopharyngeal 
swab specimen collected two months later, we reanalyzed the sample in triplicate; on the basis of 
extrapolation of the standard curve run in parallel, we estimated the viral load to be 1.3x10
9
 
genome copies/mL of nasopharyngeal swab transport media. This patient’s course was 
complicated by graft-versus-host disease of the gut and skin, renal failure requiring dialysis, and 
recurrent pulmonary hemorrhage. The patient was critically ill and had experienced multi organ 
failure at the time of the second sampling. Other microbiological test results were negative at that 
time, including PCR for Epstein-Barr virus, cytomegalovirus, human herpesvirus-6, and 
adenovirus in the blood; aspergillus antigen detection in blood; and bacterial cultures of blood, 
tracheal aspirate, urine, and peritoneal fluid. The fecal specimen collected at this time was 
negative for KIPyV; plasma and urine were not available for this study. The patient died of acute 
respiratory failure and extensive pulmonary hemorrhage 24 days after collection of this 
specimen. Despite the frequent detection of KIPyV in respiratory specimens, no studies have 
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definitively linked infection with respiratory disease. Titers of KIPyV were high in the 
nasopharyngeal swab sample from this patient three weeks before respiratory failure. Although 
this observation does not necessarily implicate KIPyV infection as a contributing factor in the 
death of the patient, it suggests a poorly controlled KIPyV infection in the respiratory tract. 
Three specimens collected from patient 4001, a 13-year-old heart transplant recipient, 
were positive for TSPyV (Figure), but the patient did not have Trichodysplasia spinulosa. At one 
week after transplant, the nasopharyngeal swab and fecal samples were positive for TSPyV. At 
one month after transplant, the nasopharyngeal swab sample was again positive for TSPyV, with 
a viral load of approximately 2.3x10
4
 genome copies/mL of transport media. There is currently 
only one TSPyV sequence in GenBank (accession no. GU989205). We used four primer pairs to 
amplify the complete genome of TSPyV from the nasopharyngeal swab taken one month after 
transplant. PCR products were cloned, and the complete genome was sequenced to 3x coverage 
(GenBank accession no. JQ723730) and compared with the other TSPyV sequence. There were 
five nucleotide substitutions:  three in noncoding regions and two synonymous mutations. 
 
Figure. Samples tested for TSPyV during May–June 2009 from patient 4001, a 13-year-old heart 
transplant recipient at St. Louis Children’s Hospital, St. Louis, Missouri, USA. Samples tested at 
each time point are indicated by white squares. Black squares represent positive samples. NP, 
nasopharyngeal. 
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Although serologic studies have demonstrated that approximately 70% of adults in 
Europe have been infected by TSPyV (13), its mode of transmission is unknown. The detection 
of TSPyV in nasopharyngeal swab and fecal samples raises the possibility that it may be 
transmitted by a respiratory or fecal–oral route. Furthermore, in the current study, two sequential 
nasopharyngeal swab samples taken 20 days apart were positive for TSPyV, suggesting it may 
persist for extended periods in the respiratory tract, at least in immunosuppressed persons. 
 
CONCLUSIONS 
Our goals were to establish a longitudinal repository of different specimen types from 
transplant recipients and to define the prevalence of polyomaviruses in these patients. We 
detected all nine polyomaviruses in at least one specimen. Although the prevalence of each virus 
was generally low, TSPyV, HPyV6, HPyV7, and MCPyV were detected in specimen types not 
previously reported. These observations expand understanding of the recently identified 
polyomaviruses and the tissue and organ systems they may infect and suggest possible modes of 
transmission. Further studies to define their possible roles in human diseases are needed. 
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